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Introduction: The wide-ranging prognostic implications of a breast cancer diagnosis highlight the need 
to better enable women to make informed decisions regarding screening and treatment options.  As 
several cancer susceptibility syndromes have been linked to germline mutations resulting in defective 
DNA repair, including the predisposition to breast cancer due to BRCA1 and BRCA2 mutations, more 
subtle defects in DNA repair capacity may contribute to the components driving differential 
susceptibility within the general population.  Hence, understanding the role of DNA repair capacity in 
breast cancer onset may aid in the development of a more comprehensive risk profile, thereby 
furthering the effort to target relevant populations for early screening. 
In the studies undertaken for this dissertation, we employed various methodologies capturing endpoints 
across different repair pathways detectable in blood to both further elucidate the etiologic basis of 
breast cancer development and leverage the information into the potential development of a screening 
biomarker. 
Methods: For the phenotypic assessment of nucleotide excision repair (NER) capacity, we developed 
an ELISA-based method to determine benzo(a)pyrene diolepoxide (BPDE)-DNA adduct capacity in 
lymphoblastoid cell lines.  Gene expression levels were assessed with pre-designed Taqman kits in 
RNA-derived cDNAs from mononuclear cells using a real-time PCR-based platform.  Methylation 
analysis was conducted with in-house designed assays on bisulfite-converted DNA from mononuclear 
cells using a pyrosequencing platform.  Finally, single nucleotide polymorphisms (SNP) genotyping was 
assessed in DNA derived from white blood cells with pre-designed Taqman SNP genotyping assays 
using a real-time PCR-based platform.  All studies were conducted in sister-sets enrolled in the New 
York site within the Breast Cancer Family Registry and all statistical analysis was conducted using the 
R Foundation for Statistical Computing (2011). 
Results:  We did not detect an association between the ELISA-based phenotypic assessment of NER 
capacity in the lymphoblastoid cells lines of the sister-sets (n=246, 114 sister-sets) and breast cancer 
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risk (OR = 1.0, 95%CI=0.95, 1.04).  Furthermore, we did not observe a correlation with previously 
determined NER capacity in the same population using an immunohistochemical-based method  
(r= -0.01, p=0.86).    
In our gene expression study (n=569, 218 sister-sets), women in the lowest tertile of ATM expression 
had a heightened risk of breast cancer compared to women in the highest tertile of expression, 
adjusted for age at blood draw and smoking status (OR=2.12, 95%CI=1.09, 4.12).  This association 
was largely restricted to women with an extended family history of breast cancer (pinteraction = 0.06).  
Additionally, women in the lowest tertile of MSH2 expression also had a heightened risk of breast 
cancer compared to women in the highest tertile of expression, adjusted for age at blood draw and 
smoking status (OR=2.75, 95%CI=1.31, 5.79).  The association observed between reductions in ATM 
expression level and breast cancer risk was lost upon incorporating previously determined end-joining 
capacity of EcoRI-generated sticky end substrates (OR=1.28, 95%CI=0.15, 11.2) and HincII-generated 
blunt end substrates (OR=1.55, 95%CI=0.15, 15.5) into the model, suggesting that the impact on risk 
due to reductions in ATM expression maybe partially driven by the reduction in double strand break 
repair capacity.   
In our study investigating breast cancer risk due to the impact of epigenetic modulation on DNA repair 
gene activity (n=569, 218 sister-sets), no association with risk was observed due to differential 
promoter methylation levels of BRCA1 (OR=1.09, 95%CI=0.98, 1.20), MLH1 (OR=1.19, 95%CI=0.91, 
1.55) or MSH2 (OR=0.89, 95%CI=0.48, 1.64).  Furthermore, no correlation between BRCA1 
methylation and expression (r=-0.05, p=0.39) or MSH2 methylation and expression (r=-0.04, p=0.39) 
was observed. 
Finally, our mismatch repair genotyping study (n=714, 313 sister-sets) indicated an association 
between the variant MutY_rs3219489 (OR=2.23, 95%CI=1.10, 4.52) and breast cancer risk, as well as 
a borderline association with risk due to the variant MSH2_rs2303428 (OR=1.71, 95%CI=0.99, 2.95).  
Furthermore, a protective effect was observed due to the variant MLH3_rs175080, restricted to women 
without an extended family history of breast cancer (pinteraction = 0.03).    
iii 
Conclusion:  These studies suggest that the deregulation of targets spanning various DNA repair 
pathways contribute to the risk of familial breast cancer. 
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Chapter I. Literature review 
Breast cancer demographics 
Breast cancer is the most common type of cancer and second leading cancer-death among women in 
the US, with one in every six diagnosed women succumbing to the disease
1
.  Treatment options 
include lumpectomy or mastectomy, often followed by a regimen including any or all of chemotherapy, 
radiation therapy and hormone-therapy.  As with all cancers, breast cancer is most treatable prior to the 
clinical manifestation of the disease.  In addition to a successful overall outcome, the state of 
progression of the disease at the time of diagnosis also impacts the quality of life, dictating the duration 
and severity of the regimen required during treatment.    Hence, early detection of this disease is of 
vital importance.  
Routine mammography is the recommended screening method of choice for early detection of breast 
cancer.  Using this technique, 80-90% of women with breast cancer can be diagnosed prior to the 
presentation of clinical symptoms
1
.  However, there are limitations to the technology.  Patient 
characteristics, including age, presence of micro-calcification and dense breast tissue, can obscure 
detection, contributing to the up to 20% of asymptomatic cases who will remain undiagnosed despite 
regular screening
2
.  In addition to sensitivity concerns, there are also issues regarding the specificity of 
the methodology.  Fifty percent of women receiving yearly mammograms will receive a false positive 
diagnosis during their lifetime
3
.  In fact, a majority of women with abnormal mammograms do not have 
cancer, necessitating biopsies to confirm the test result
4
.  The implications of a positive diagnosis and 
need for further invasive tests likely contributes to undue stress and anxiety. 
Lastly, there is a suggested trend towards overdiagnosis and overtreatment based on mammography.  
Up to 30% of cancers detected are, in fact, non-invasive cancers and pre-malignant lesions with a low 
proliferative index
5
.  Intervening on such cases with the prescribed treatment of surgery, chemotherapy, 
radiation and/or hormone therapy likely provides little benefit, and may, in actuality, be harmful due to 
the duress involved
6,7
.  Consequently, the reliance on the diagnostic capabilities of mammograms has 
mainly led to the treatment of cases with generally favorable prognosis, at the cost of missing women 
who present at a younger age and with rapid tumor growth
8
.   
2 
 
In the US, annual mammograms are recommended starting at the age of 40.  In addition to the 
aforementioned inherent limitations in the technology, implementation of the current standard is 
complicated by the fact that risk is not equivalently distributed throughout the population.   For a woman 
with a lower likelihood of developing aggressive breast cancer prior to menopause, screening less 
frequently and starting at a later age may be sufficient and decrease the likelihood of overdiagnosis 
and overtreatment.  However, for others, more active surveillance than the current recommendations 
may be necessary for successful intervention.  Such measures could include the option of prophylactic 
mastectomy and tamoxifen treatment.  In fact, tamoxifen has been shown to reduce breast cancer 
incidence by up to 50% among high-risk women.  However, the side-effects associated with long-term 
treatment with such chemopreventive agents are not trivial, including risk of endometrial cancer, 
pulmonary emboli and menopausal symptoms
9
.    Hence, there exists a need to provide adequate 
information regarding the costs and benefits relevant to the given situation, enabling women to make 
more informed decisions regarding screening and intervention strategies.  Fulfilling this imperative will 
require a more thorough understanding of the underpinnings of the disease to better profile women into 
more clearly defined risk categories. 
Known risk factors of breast cancer 
A number of risk factors contributing to breast cancer risk have been identified thus far
10
.   As with 
many other cancer-subtypes, breast cancer risk increases with age, as few women below the age of 30 
present with the disease.  A number of theories have been put forward to explain the observed 
relationship.  These include age-related hormonal changes, failing immunologic surveillance over time 
and the effect of environmental insults accumulated throughout the life-span
11
. 
Approximately 20% of risk is attributed to having a family history of breast cancer
12,13
.  The increasing 
risk with increasing numbers of first-degree relatives is further enhanced the earlier the relative 
presented at the age of diagnosis
14
. The observed clustering of cases within families could be 
attributed to shared inherited and/or lifestyle and environmental factors. Twin studies have sought to 
address the degree to which genetic and non-genetic factors contribute to familial risk by capitalizing 
on the fact that monozygotic twins have identical copies of genetic information while dizygotic twins 
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share only half the information.  Meanwhile, the degree to which non-genetic factors are shared is likely 
not differentiated by zygosity.   Hence, an overriding genetic influence should be reflected by greater 
concordance among monozygotic twins, while an equivalent concordance would suggest that shared 
non-genetic factors play a more active role.  A number of such studies have, in fact, shown a greater 
concordance for breast cancer among monozygotic twins than dizygotic twins, suggesting that familial 
presentation of the disease is mainly driven by genetic components
15,16
.   
The identification of germline mutations in the tumor suppressor genes BRCA1 and BRCA2 have been 
key in delineating the genetic components mediating a role in familial breast cancer
17
.  Women who 
inherit mutations in these genes have up to an 85% chance of developing the disease by the age of 
70
18
.  However, due to the rarity of such mutations, only 5% of the risk posed by family history of the 
disease is believed to be attributed to the loss of function of these genes, highlighting the large 
proportion of risk that has yet to be accounted for
17
.   
Various reproductive factors have been shown to play a role in risk as well.  In a case-control study 
drawn from a nationwide screening program, increasing age at menarche was associated with 
decreasing risk, with a 23% reduction in risk among women with an age at menarche after the age of 
15 compared to women with menarche before the age of 12.   The same study also demonstrated a 
heightened risk for pre-menopausal women compared to post-menopausal women, and induced 
menopause through bilateral ooppherectomy afforded even greater reduction in risk
19
.   Parity also 
exerts a protective effect
20
.  However, the reduction in risk among parous women compared to nulli-
parous women is attenuated with increasing age at parity
21
.   It has been suggested that the means by 
which these reproductive factors mediate an effect on breast cancer risk may involve the influence on 
mammary gland differentiation.   During development, undifferentiated epithelial cells in the mammary 
gland undergo rapid proliferation, heightening the region’s susceptibility to carcinogenic agents.  This 
undifferentiated proliferative state continues until the final stage of pregnancy, at which point terminal 
differentiation is initiated.    Hence, early age at menarchy and late age at first pregnancy are factors 
which may broaden the window of susceptibility during which the accrual of hits can lead to 
transformation
22
.   
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In addition to intrinsic traits, efforts have been made to identify environmental and lifestyle factors as 
potential intervention endpoints to reduce risk.   One such factor includes lifetime exposure to estrogen, 
which has been implicated through various routes.  Exogenous administration of estrogen was 
commonly prescribed with hormone replacement therapy (HRT) for the management of menopausal 
symptoms.  Several studies have now shown that HRT use within the past 5 years is significantly 
associated with increased breast cancer risk
23,24
.   
Estrogen exposure may also exert a more indirect influence on breast cancer risk by mediating the 
observed association with obesity.  While higher body mass index (BMI) is considered a risk factor 
among postmenopausal women, it is considered a protective factor among premenopausal women
25,26
.   
This differential effect may be due to the bioavailability of circulating estrogen.  In premenopausal 
women, estrogen production is primarily mediated by the ovaries, which maintain the level of freely 
circulating estrogen under tight homeostatic regulation
27
.  In postmenopausal women, there is an 
increase in extraglandular estrogen production, including in adipose tissue, where the level of freely 
circulating estrogen is not as strictly regulated.  Hence, higher BMI leads to a concomitant rise in 
estrogen bioavailability, which in turn, has been linked to an increase in breast cancer risk among 
postmenopausal women
28
.  The association is further substantiated by the fact that postmenopausal 
women are more likely to develop estrogen-dependent tumors compared to premenopausal women, 
and may, therefore, be more responsive to the mitogenic effect of an obesity-induced increase in 
estrogen level
29
.    
Radiation exposure is the most significant environmental agent associated with breast cancer risk, 
though the risk is far more attenuated than what has been reported with other more typically linked 
radiation-induced  cancer sub-types, including leukemia and thyroid cancer.  Still there are special 
implications for vigilance despite the incremental increase in risk in breast cancer, as both monitoring 
and treating disease require radiation exposure
30,31
.    
Using these currently known risk factors, models have been developed to generate approximate risk 
profiles with the purpose of allowing women and practitioners to make more informed choices in 
selecting screening and intervention strategies.  The Gail model is one such popularly used model 
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which incorporates established risk factors and accounts for possible synergy between them.  Included 
in the model are family history, late age at childbirth, early menarche, multiple benign biopsies, all 
modified by age
32,33
.  However, as each of these factors account for only a modest proportion of risk, 
the models generated based on these risk factor lack adequate predictive power
10
. 
Much attention has been paid to identifying additional factors, particularly genetic components, to 
improve upon such models.  However, isolating areas of deregulation that have a meaningful impact on 
disease susceptibility requires an understanding of the underlying processes involved in the onset and 
progression of breast cancer.      
Hallmarks of cancer 
Like all forms of carcinogenesis, breast cancer arises from a multi-step process, enabling the out of 
control growth of abnormal cells.  This entails the sequential transformation of normal cells into a 
premalignant lesion, a subset of which progress to a localized tumor, a further subset of which evolve 
into an invasive tumor, out of which an additional set of changes can result in ultimate metastasis.  
While the specific steps from initiation to progression vary from case to case, they can be categorized 
according to a common set of hallmarks met to transform a normal cell into a neoplastic one.   The first 
among these is the ability to continually proliferate.  Under normal conditions, entry and progression 
through the cell-cycle is tightly regulated, with specific growth signaling cues necessary to initiate 
replication.  In addition to the specific signals needed to trigger replication, the regulation of cell-cycle 
entry is further enforced by growth suppressor signaling.   These signals are also key in ensuring that 
replication only progresses once proper functioning of cellular processes has been verified.  
Transformed cells acquire the ability to overcome both checkpoints, and the ensuing abnormal 
proliferation of normal cells can be observed in the breast as hyperplasia
34
.  In the presence of 
insurmountable physiologic stressors, such as the accumulation of irreversible DNA damage, normal 
cells are wired to trigger apoptosis to prevent further deregulation and propagation of the resulting 
instability. During the transformation process, cells acquire the ability to desensitize themselves from 
this signaling cascade, thereby, furthering the transformative potential of these cells by enabling the 
continued unchecked accrual of genetic alterations.  Normal cells are also restricted in the number of 
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divisions they undergo prior to senescence, a state in which the cells remain viable but no longer 
proliferative.  Transformed cells overcome this restriction on cell cycles, enabling replicative 
immortality.  Once a mass of transformed cells has developed, a means of sustenance and waste 
removal is required.  For this purpose, angiogenesis, a process normally quiescent in adult cells, is 
induced to provide nutrient and oxygen access to the tumor as well as waste and CO2 removal from the 
tumor.  In the breast, atypical growths that have accumulated these qualities present as non-invasive in 
situ tumors
34
.   Higher grade tumors acquire the additional ability to delocalize and invade neighboring 
tissues, a process facilitated by the reduction in expression of adhesion molecules.  This occurs locally 
at first, then distally with the entrance and transit through the blood and lymphatic systems, providing 
the metastasized cancer access to more distant sites
35
.   
Mutator phenotype  
As indicated by the outlined steps for the hallmarks of cancer, a sequential accrual of alterations in key 
genes is required for transformation to go to completion.   However, based on the estimated 10
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spontaneous mutations/nucleotide/division mutation rate, the number of alterations accumulated within 
a lifetime would fall short of the multiplicity of mutations typically observed in tumors.  Hence, it has 
been suggested that the presence of a mutator phenotype may facilitate the process early on by 
increasing the inherent mutation rate
36
.  Several potential candidates whose altered state could lead to 
a mutator phenotype have been suggested.  Key among them are genes involved in maintaining the 
fidelity of the genome.   
DNA repair as a candidate target for a mutator phenotype 
Instructions for the essential functions of each cell are held within the genome through the specific 
arrangement of a four-letter code consisting of adenine, thymine, guanine and cytosine.  As the 
blueprint of life, it is vital that these instructions are preserved and faithfully transmitted for the proper 
functioning and propagation of all living-things.  These instructions are held within DNA molecules, 
consisting of two polynucleotide chains wound around each other in a double-stranded helix.  The 
chains are held together by hydrogen bonds between the purine and pyrimidine side-chains of DNA, 
with adenines always matched with thymines and guanines always matched with cytosines.  Strict 
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adherence to these base-pairing rules allows the sequence along one chain to be determined based on 
the sequence of the other.  Through this redundancy in information, replication can progress with the 
separation of the duplex and use of the parental strands as templates to synthesize complimentary 
strands.  Hence, the inherent structure of DNA facilitates the transmission of the genome during the 
numerous replication cycles cells undergo throughout a lifetime
37
.   
However, maintenance of this structure is compromised through various processes, including 
endogenous sources such as spontaneous deamination, cellular metabolism and replication error as 
well exogenous sources of oxidative stress, ionizing radiation and pollution
38–43
.  To retain genomic 
integrity in the face of these various threats, organisms have evolved repair processes that recognize 
and remove such changes in the chemistry of DNA.  Hence, mutations in these genes would tend 
towards greater overall genomic instability, increasing the baseline mutation rate and facilitating the 
accumulation of changes necessary to develop cancer.   
Initial findings outlining the effects associated with deficiencies in DNA damage recovery stem from 
experiments conducted in mutant E.Coli strains
44–46
.  These repair-deficient strains were shown to be 
hyper-responsive to environmental agents.  Establishing a similar link within a human population, 
however, was complicated by the fact that such mutants are unlikely to be found in a natural setting 
due to the severity of the phenotype associated with such a defect.  However, a few rare inherited 
human disorders do present with a heightened sensitivity to environmental agents.  One such example 
is Xeroderma Pigmentosum (XP), a condition that results in an up to 1000-fold increase in risk of 
developing skin cancer due to sunlight exposure
47
.  Studies have shown that while cells from normal 
and XP individuals start out with an equivalent number of lesions following UV-irradiation, a greater 
proportion of the lesions persist over time in cells from XP individuals compared to normal individuals, 
indicating that the observed sensitivity is due to a defect in damage repair
48
.   
Subsequent studies established that repair consisted of multiple components, and that different types 
of damages are targeted by specialized pathways
49,50,51
.  Currently, four distinct, yet partially 
overlapping, types of repair pathways have been identified: Nucleotide excision repair, double-strand 
break repair, base excision repair and mismatch repair. 
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Nucleotide excision repair  
Nucleotide excision repair (NER) is regarded as one of the most versatile types of the repair pathways, 
recognizing a wide range of lesions.  Unlike other excision repair pathways, NER does not rely on the 
specificity of enzymes to uniquely recognize individual lesions, instead focusing on more general bulky 
distortions to the helix, enabling the versatility of the pathway.  The major form of defense is directed 
against DNA lesions that result from UV light exposure, which induces covalent bonds between 
adjacent pyrimidines to form dimers.  Also targeted are lesions due to chemicals that covalently bind 
DNA, forming adducts.  Exposure routes for such chemicals include food-intake, as in the case of the 
mold-produced aflatoxin, as well as air inhalation, as in the case of smoke-related benzo(a)pyrene.  In 
many of these instances, the parent chemical compound itself is innocuous.  The toxic effects are, in 
fact, mediated by the intermediary metabolites produced during the process of eliminating these 
compounds from the system
52
. 
NER mediates detection and removal of such lesions via two processes: The global genome repair 
(GGR) arm of the pathway is initiated upon damage-detection during a genome-wide survey, whereas 
the transcription-coupled repair (TCR) arm of NER is initiated upon damage-detection during the 
specific interrogation of actively transcribed regions
53
.  In GGR, XPC complexed with Rad23-centrin 
and CETN2 facilitates recognition of damage in conjunction with the UV-damaged DNA binding protein 
complex containing DDB1 and DDB2
54,55
.  The DNA is unwound around the lesion by the XPB and 
XPD subunits of TFIIH
56
, while XPA and RPA act to stabilize the ssDNA, forming a 27 nucleotide 
bubble
57,58
.  The endonucleases XPG and ERCC1-XPF cleave the DNA 3’ and 5’ to the lesion, 
respectively, generating a 24-32bp fragment
59,60
.  The ensuing gap is filled by PCNA-dependent DNA 
polymerases δ/ε
61–63
, and the nick is sealed by DNA ligase III-XRCC1
64
.  In contrast to GGR, TCR is 
believed to be initiated upon RNA polymerase II encountering a lesion during transcription.  Stalling of 
the polymerase triggers the assembly of various factors, including CSB, CSA and TFIIS
65
.  Following 






Base excision repair  
Minor base alterations, causing slight distortions to the helix, are primarily targeted by base excision 
repair (BER).  Examples of such alterations include depurination, resulting in the formation of abasic 
sites, deamination of cytosine to uracil, alkylation of adenine to 3-methyl adenine, and oxidation of 
guanine to 8-oxoguanine.  Agents capable of such changes are readily found within the cellular 
environment in the form of oxidative stress due to normal metabolic activity and the presence of 
endogenous S-adenosylmethionine (SAM) as an alkylating agent, but can also be elicited exogenously 
through ionizing radiation-induced oxidative stress and tobacco smoke-related alkylation 
67
.  The 
resulting modifications cause the replication machinery to stall at the lesions, triggering eventual 
apoptosis.  If bypassed, however, many of these lesions can prove to be mutagenic, with the 
resemblance to alternate bases resulting in miscoding in subsequent replication cycles.  This is 
especially the case for 8-oxoguanine, which as a thymine-mimic, can base-pair equally well with 
cytosines and adenines, leading to a potential GC:TA transversion.
68
 
BER consists of a six-step process: damage recognition, removal of the distorted base, nicking of the 
DNA backbone, strand processing, polymerase refilling, and resealing by DNA ligase.  Damage 
recognition is facilitated by a family of damage-specific DNA glycosylases.  During this process, the 
DNA backbone is pinched, such that the nucleotide flips out and into the substrate-binding pocket of 
the glycosylase.  Successful recognition catalyzes a series of reactions, starting with the glycosylase-
initiated cleavage of the N-glycosyl bond between the base and DNA backbone, forming an 
apurinic/apyrimidinic (AP) site.  Bifunctional DNA glycosylases have an intrinsic AP lyase activity, 
enabling them to nick the DNA backbone 3’ to the AP site following removal of the base, while in the 
case of monofunctional DNA glycosylases , an AP endonuclease (APE) enzyme is recruited to incise 
the DNA backbone 5’ to the AP site.  In either case, the 3’-phosphodiesterase activity of the APE 
enzyme further processes the nicked strands to reveal the 3’-OH group necessary for subsequent 
polymerase β elongation of the strand with the appropriate nucleotide.  DNA ligase is then recruited to 
seal the remaining nick.  Subsequent to the initial incision, BER can progress along two possible 
pathways, short patch repair, involving the replacement of a single nucleotide, or long patch repair, 
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resulting in the re-filling of a widened 2-8 nucleotide gap and involving the recruitment of additional 
enzymes for processing .
69
 
Mismatch repair  
Mismatch repair (MMR) is initiated in the presence of base-pairing that contradicts the standard A-T/C-
G Watson-Crick base-pair patterns (GA/CA/TC/TG/GG/CC/TT/AA).  These can arise in instances of 
replication-induced errors, spontaneous deamination, as well as cellular metabolism-related oxidative 
stress.  Replication-related errors occur through the misincorporation of a base, leading to a single 
base:base mismatch, as well as through a misalignment of the polymerase with the template, leading 
to insertion/deletion loops (IDLs).  Mutations that arise as a consequence of such replication-related 
errors  are kept to a minimum by the fidelity of DNA polymerases to incorporate correct nucleotides, 
which is reinforced by an inherent proofreading mechanism that enables detection and excision of any 
mispaired bases prior to the incorporation of subsequent nucleotides, thereby, ensuring maintenance of 
base-pair integrity.  Still, in a genome consisting of 3x10
9
 bases, the resulting estimated error rate of 1 
in every 10
7
 bases translates to the introduction of hundreds of alterations with each replication cycle
70
.  




, one that is more tolerant to human cells, is 
realized downstream of the replication fork through the complimentary activities of the MMR system.   
A key distinguishing characteristic of post-replicative MMR from other types of excision repair is that 
while the response is initiated by distortions in the helix, the mispaired constituents of the distortions 
are both chemically-normal bases.  Hence, correctly identifying the base for removal adds a layer of 
complexity to MMR not faced by the other pathways.   In replication-associated errors, the key lies in 
discriminating the newly synthesized strand from the parent template.  How this is accomplished in 
eukaryotic cells  remains to be confirmed, however, the presence of strand discontinuities in the 
nascent strand may play a role
71
. 
The presence of chemically-modified bases is an additional source of mispairing.   Such modifications 
can either result in altering the base to a form that favors alternative binding partners from the one 
prescribed by traditional Watson-Crick base-pairing or converting the base into another naturally 
occurring base, maintaining Watson-Crick base-pairing rules in subsequent replication cycles, albeit 
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different from the ones prescribed for in the original code.  Alkylating agents, for example, can induce 
methylation of guanines to form O6-methyl guanine, which binds equally well to dcAMP and dtAMP, 
and oxidation of guanines generates 8-oxoguanines, which favor binding daAMP over the originally 
dictated dcAMP.  Meanwhile, 5-methyl cytosines base-paired with guanines can spontaneously 
deaminate to generate thymines, altering the original GC basepair to a TA basepair in subsequent 
replication cycles. 
Chemical modifications can occur in bases already incorporated into the genome, as well as to 
nucleotides in the dNTP pool.  Hence such modifications threaten the integrity of the genome on two 
separate fronts: through the incorporation of altered bases during replication as well as subsequent 
alteration of correctly incorporated nucleotides following replication.   
 Depurination and depyrimidation present special case scenarios for generating mismatches.  The 
resulting non-instructive abasic sites cause DNA polymerases to stall during replication.  In such 
instances, random nucleotides are incorporated and tolerated to avoid collapse of the replication fork. 
There are various components involved in the pathway of mismatch repair.  MMR is initiated through 
the recognition of the mismatch by one of two heterodimers.   The MSH2:MSH6 heterodimer 
preferentially targets base:base mismatches and short IDLs while the MSH2:MSH3 heterodimer 
identifies longer IDLs.   Binding of either heterodimer recruits the MLH1:PMS2 heterodimer.  The ATP-
driven conformational change allows this heterodimer to slide along the strand away from the 
mismatch.  PMS2, in the presence of RPA, PCNA and ATP, introduces nicks in the mismatch-
containing strand, with the generated fragment degraded by EXO1.  The gap is filled by DNA polδ and 
sealed by DNA ligase I
71
. 
Double-strand break repair  
Double-strand breaks present as both a necessary means of genetic diversification, during meiosis
72
 
and  V(D)R recombination
73
, as well as the most lethal form of DNA damage, in which the information 
lost cannot be recovered from the same molecule, as with other types of damages
74
.  Two major 
pathways, homologous repair (HR) and non-homologous end-joining (NHEJ) repair, remediate double-
strand breaks.  The type of response invoked is dictated by the presentation of the damage.  A break 
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may be encountered during replication, at which time the intact sister chromatid will likely be within the 
vicinity of the replication fork, increasing the feasibility of homologous recombination
75
.  A homologous 
template, however, may not be as readily accessible for the repair of double-strand breaks generated 
during other stages of the cell cycle.  Direct induction of such breaks, incurred through such sources as 
ionizing radiation and mechanical stress
76
, generally produce two ends in close proximity to one 
another, which can be rejoined without the reliance on a repair template.  Although sequence 
information can be lost in this process, this loss is tolerated over the potentially more grievous 




NHEJ is initiated by the binding of the ku7/ku80 heterodimer to the termini
77
.  Once the ends have been 
aligned, the heterodimer recruits DNA-dependent protein kinase catalytic subunit (DNA-PKcs).  Upon 
binding, the kinase is activated
78
.  If the ends are directly ligatable, the XRCC4-DNA ligase IV complex 
is recruited to join the ends
79
.   However, various different ends can be produced, as is the case with 
ionizing radiation where reactive oxygen species (ROS) can lead to additional base and sugar 
damage
76
, and the necessary 3’-hydroxyl and 5’-phosphate groups may not be readily available for 
ligation.  In such instances, an intervening processing step prior to ligation is included, in which 
endonucleases such as Artemis are recruited to produce the required ligation substrates
80
 .   Any 
remaining single-stranded gaps are filled in by polymerases  λ and μ and terminal deoxynucleotidyl 
transferase (TdT), which can perform template-independent nucleotide extensions
81
.   
In HR, broken ends are first detected upon interaction with the Mre11-Rad50-NBS (MRN) complex.  
Upon contact with the DNA, this complex bridges and initiates processing of the termini into 3’ ssDNA 
overhangs through 5’-end resection
82,83
.   It also recruits and activates the damage signal transducer 
ATM, which then phosphorylates several downstream components of the pathway
84
.  RPA binds to the 
single-stranded overhangs eliminating secondary structures at the termini
85
.  Subsequently, a 
BRCA1/BRCA2/PALB2 containing complex facilitates  loading of the Rad51 recombinase protein
86
, 
displacing RPA and enabling the ends to invade the nearby sister-chromatid
87,88
.  The displacement of 
one strand and pairing with the other forms the heterduplex displacement loop (d-loop).  Once a 
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homologous region has been found, the invading end can be used as a primer for polymerase 
synthesis.  Through this strand exchange, the lost information of the damaged strand can be recovered 
from the undamaged strand. 
DNA repair and cancer 
In addition to XP, several other genetic syndromes manifest in individuals with heightened sensitivities 
to environmental agents.  Individuals with ataxia telangiectasia are sensitive to x-ray exposures and 
present with progressive ataxia, dilated vessels of the eye and immune deficiencies.  Individuals with 
Fanconi’s anemia are sensitive to DNA cross-linking agents and present with hematological 
abnormalities.  Despite heterogeneity in clinical symptoms, all three are linked by the fact that they 
result from defects in factors involved in DNA repair and are all cancer-prone, establishing the 
carcinogenic potential of defective DNA repair
89
.  The rarity of such genetic syndromes, however, limits 
the population-wide significance of the findings from such studies.  Still, less severe deficiencies in 
components related to DNA damage repair may be more prevalent in the population and are likely to 
have a more public health-relevant impact on the risk of various cancer sub-types, including breast 
cancer. 
Assays determining DNA repair 
The ability to assess inter-individual variations in repair is limited by the technology available to detect 
such differences.  Early studies linking genetic defects in repair with carcinogenesis focused on gross 
abnormalities resulting in the complete loss of function of genes involved in repair processes.  Once the 
association was established, more refined analyses could be conducted to identify factors with more 
subtle influences on repair.  The genetic defects leading to the aforementioned genetic syndromes 
typically arise due to missense substitutions and frameshift deletions in critical regions of the genes, 
often resulting in premature truncation
90,91
.  These alterations could be pin-pointed based on genetic 
analyses comparing individuals with clear-cut presentations of phenotypic defects and apparently 
normal individuals.  Alterations in genetic sequences resulting in a more attenuated reduction in repair-
related activity are less likely to have a readily apparent phenotype associated with it, making this 
approach of identifying relevant mutations less feasible in such situations.  However, with the aid of 
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technological advancements in sequencing, additional variants have now been mapped.  These single 
nucleotide polymorphisms (SNPs), occurring at greater frequencies but with less apparent phenotypic 
implications, can now be evaluated for health effects.   
The genotyping assays utilized to evaluate SNPs can be carried out in a high-throughput format, 
hence, utilizing this approach serves as an attractive option to determine repair capacity within a 
population-based setting.  Consequently, a number of studies have attempted to identify 
polymorphisms that may account for inter-individual differences in repair.  However, few relevant SNPs 
have thus far been identified, often with borderline associations.  This is likely due to the complex 
interplay between various gene products, introducing the difficulty of extrapolating final phenotype from 
the given genotype.   
An alternative to focusing on the genotypic level rests on the use of phenotypic assays to query 
variations at the level of protein function, integrating interacting pathways and enzymes, and thereby, 
providing a more comprehensive determination of repair capacity
92
.  Indeed associations observed in 
studies utilizing phenotyping assays are generally much more robust than what is typically observed in 
SNP studies.  However, currently available phenotyping methods, including the host cell reactivation 
(HCR) assay, are time-consuming and tedious to carry out, limiting their potential to be applied in a 
population-based setting.   
Factors impacting repair  
Both genotyping and phenotyping methods have been implemented to determine inter-individual 
variability in repair.  The presence of such variability has been observed even within apparently healthy 
populations.  In a study conducted among 102 non-Hispanic white control individuals enrolled in a 
case-control study, a 4-fold variation in the ability to repair UV-induced damage, a substrate targeted 
by NER, was determined using HCR
93
.  This variability has been observed in other repair pathways as 
well.  In an antioxidant intervention study, 48 healthy adults between the ages of 18-30 were enrolled to 
study the impact on BER capacity following micronutrient supplementation.  BER was measured using 
a modified COMET assay, in which lysed and plated HeLa cells were treated with UV light and 
incubated with lymphocyte extracts from the participants.  Differences in the amount of single-strand 
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breaks, as determined by the COMET assay, between cells incubated with and without extracts were 
used as indicators of BER capacity.  Baseline measurements using this approach showed considerable 
amount of variation, with the extent of tail DNA, a measure of DNA damage, ranging from 0.6-25%
94
.   
Given the presence of variability in repair capacity, a number of studies have sought to identify factors 
involved in the modulation of the repair response within the general population.  The impact on NER 
capacity due to the presence of polymorphisms in NER-relevant genes was assessed among 102 
healthy individuals.  Homozygosity in several of the tested SNPs led to a reduction in repair capacity as 
determined by the HCR assay, reaching statistical significance for XPC[poly(AT) intron 9]
95
.  The 
potential impact of polymorphisms in these genes on repair capacity is further substantiated by the 
higher adducts levels observed among individuals with SNP variants in NER-related genes
96,97
.  
Several studies have indicated an association between increasing age and decreasing DNA repair 
capacity, possibly suggesting a means by which cancer incidence increases with age.  The existence 
of a link between DNA repair and aging is most clearly seen in the DNA repair related genetic 
syndromes Ataxia Telangiectasia and Cockayne Syndrome, both of which include premature aging as 
a characteristic clinical feature among affected individuals.   Another means by which aging and DNA 
repair have been associated with one another is through the free radical theory of aging, which 
suggests that manifestations of aging are related to the accumulation of damage due to oxidative 
stress.  Reductions in repair capacity could overwhelm the system with the challenge imposed by free 
radicals, enabling the accumulation of DNA damage over time to account for the overall decline 
associated with aging. Such a reduction in repair with time has indeed been shown in a case-control 
study investigating risk for basal cell carcinoma, where a nearly 25% decline in NER capacity was 
noted among 60-year old controls compared to 20-year old controls
98
.   
In addition to these intrinsic factors, several modifiable factors have also been identified.  Since 
nutritional status has a putative role in cancer risk, studies have sought to assess whether dietary 
factors also modulate DNA repair capacity.  To date, there have been varied reports of stimulatory, 
inhibitory and no effects on repair, depending on the pathway and dietary factor tested.  However, in 
one of the largest studies addressing this question, 559 non-Hispanic white cancer-free individuals 
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from the Houston metropolitan area were analyzed for the impact of folate status, derived from food 
frequency questionnaire data.  DNA repair capacity in these same individuals was assessed using the 
host cell reactivation assay.  In this study, an 18% reduction in repair capacity was observed among 
individuals in the lowest tertile of folate levels compared to individuals in the highest tertile
99
. 
While the increase in oxidative stress resulting from exercise-induced aerobic metabolism is well-
recognized, few studies have addressed whether the accumulation of oxidative stress-related damage 
as a result of physical activity also has implications on DNA repair capacity.  In a study conducted 
among marathon runners, the activity of OGG1 was increased in skeletal muscle following a marathon 
race, suggesting an adaptative response of increased 8-oxoG excision to meet the challenge imposed 
by the increased presence of free radicals
100
.  However, the study relied on measurements in only 6 
subjects, limiting the conclusiveness of the data. 
Finally, exposures to various environmental agents have also been shown to mediate an effect on DNA 
repair.  In a lung cancer case-control study, current smokers were observed to have the highest DNA 
repair capacity among both cases and controls, suggesting that exposure to damage-inducing 
environmental agents may induce repair activity
101
. 
Defects in DNA repair pathways have implications for breast cancer 
Using these approaches, a number of studies have established links between deficiencies in DNA 
repair capacity and breast cancer risk.  Most notably, the major breast cancer susceptibility genes 
BRCA1 and BRCA2 are both associated with DSBR.  In fact, these two genes are implicated in 
facilitating the HR branch of the pathway.  Interestingly, no such high-penetrant effects have been 
identified for genes involved primarily in the NHEJ branch of DSBR, although a modest increase in risk 
associated with several SNP variants located in NHEJ genes have been observed
102
.   
Phenotypic assessments of repair have also demonstrated a role for double-strand breaks in breast 
cancer risk.  Several studies have shown a greater accrual of damage among breast cancer cases 
compared to controls following exposure to DSB-inducing agents.   In one such study, the number of 
chromatid breaks in peripheral blood lymphocytes immediately following X-irradiation was similar 
between breast cancer cases and controls.  However,  following a recovery period, the number of 
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breaks detected in the controls diminished over time, while a greater number of breaks were retained in 
the cases, indicating a deficiency in the ability to repair such damage
103
.  Additionally, a number of 
case-control studies assessing overall EJ capacity using an in vitro functional assay have observed an 
up to 3-fold increase in breast cancer risk among women with the poorest EJ capacity
104,105
.    
The major hallmark shared by all NER-related genetic syndromes
106,107
, which in addition to  XP include 
Cockayne syndrome and trichothiol dystrophy
106
, is photosensitivity.      While the resulting 
predisposition to skin cancer due to NER-related deficiencies has been well-established, associations 
with additional cancer subtypes, including breast cancer, have been observed as well.   A study 
conducted in Puerto Rico measured NER capacity among breast cancer cases and controls using the 
HCR assay and reported a 36% reduction in repair capacity (p<0.001) among the cases compared to 
controls
108
.  Similarly, a study was conducted within discordant sister-sets enrolled in the New York site 
of the Breast Cancer Registry which assessed NER activity using an immunohistochemical method to 
measure the removal capacity of benzo(a)pyrene diol epoxide (BPDE)-DNA adducts, a substrate for 
NER.  This study also reported a significant reduction in repair capacity among cases compared to their 
control sisters, with a more than two-fold increase in breast cancer risk among subjects with repair 
levels below the median of the controls
109
. 
The earliest indications linking MMR to carcinogenesis were recognized in studies focusing on patients 
with Lynch syndrome, a predisposition towards hereditary nonpolyposis colorectal cancer (HNPCC) as 
well as several other extracolonic cancers including ovarian, endometrial and gastric cancer
110
.  These 
studies frequently observed a particular microsatellite phenotype, with the short repetitive motifs 
distributed throughout the genome often varying in lengths in the tumors of these patients
111
.  This type 
of replication error occurs as a result of polymerase slippage, with the primer and strand dissociating 
from one another, only to reassociate with one another misaligned, leading to potential insertions or 
deletions of repeats in the nascent strand.  The resulting errors observed within such sites may 
themselves promote carcinogenesis, if located within critical genes whose function are disrupted by the 
altered alignment, or may be indicative of a general genome-wide instability.  Hence, while such errors 
may constitute part of a normal phenomenon during replication of these sites, such mistakes are likely 
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readily corrected with a mechanism that seems to be impaired in these individuals.  This mechanism 
was subsequently identified in linkage analysis studies of tumors derived from Lynch family patients 
which pinpointed the phenotype to three particular loci in the genome, later identified as MLH1, MSH2 




.  It has now been established that cancers arising in this 
particular population arise as a consequence of a genetic predisposition leading to loss of function in 
genes critical to MMR function. 
While cancer susceptibility due to failures in MMR has been most strongly associated with Lynch 
syndrome related cancers, there are some indications that deficiencies of this repair pathway may also 
have implications for breast cancer.  The greatest weight of evidence is derived from studies observing 
that a substantial proportion of analyzed breast tumors present with microsatellite instability (MSI)
115
.  
However, unlike Lynch syndrome-associated cancers, few studies have been able to implicate a 
genetic predisposition due to defects in MMR genes to breast cancer susceptibility. 
Unlike other DNA repair pathways, genes involved in BER have, thus far, not been implicated with a 
genetic susceptibility to cancer.  While an increased mutator phenotype has been observed in bacterial 
and yeast mutants, mice with BER targeted knock out genes present with a near normal phenotype.  
This has been attributed to the likely redundancy of the various enzymes, with the overlap in 
functionality minimizing the effect of a deficiency in any one single component.
69
   Still, a few 
epidemiological studies do indicate a potential role for BER deficiency and human carcinogenesis.  In a 
case-control study conducted in Israel, individuals in the lowest tertile of enzymatic activity of OGG1, 
the DNA glycosylase responsible for targeting oxidative stress-induced 8-oxoguanines, were found to 








Significance of study 
1. To improve risk assessment by better identifying individuals with suboptimal repair, thereby 
enhancing the targeted screening of susceptible individuals 
2. To provide a more thorough understanding of the means by which deficiencies in DNA repair 
bear relevance on breast cancer susceptibility, facilitating identification of interventional 
endpoints. 
DNA repair mechanisms are vital to maintain the integrity of the genome in the face of continual 
exposure to damaging agents in the exogenous as well as endogenous environment.  Reduced repair 
capacity compromises the stability of the genome, allowing incurred alterations to persist.  As these 
changes serve as potential initiators of carcinogenesis, DNA repair capacity can serve as a marker of 
breast cancer susceptibility. 
In fact, it has already been shown that women at high risk due to a family history of breast cancer have 
five times the likelihood of suboptimal DNA repair compared to women with minimal family history of 
breast cancer
117
.  These preliminary observations call for a need to establish high-throughput functional 
assays capable of assessing repair as a means to screen individuals with an increased risk of cancer 
due to a heightened sensitivity to carcinogenic exposure.  
Current phenotypic assays measuring DNA repair are labor intensive and not applicable to large scale 
population studies.  To address this need, we intend to develop a NER capacity assay using a 
competitive ELISA-based method to determine the in vitro removal of DNA adducts induced by BPDE, 
a metabolite of the polycyclic aromatic hydrocarbon benzo(a)pyrene, commonly found in cigarette 
smoke, exhaust fumes and char-boiled food
118
.   
Various groups, including our own, have already reported findings implicating suboptimal repair 
capacity, as indicated by mutational analysis, genotyping studies, epigenetic studies and gene 
expression studies of specific DNA repair-related endpoints, as well as phenotyping assays indicative 
of overall repair capacity, with breast cancer susceptibility.  However, how alterations in these 
individual components integrate into the overall observed reduction in pathway activity, and how all of 
these factors ultimately translate into the observed increase in breast cancer risk, has not yet been 
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established.  For this purpose, select intervening factors that may explain currently available data 
implicating DNA repair and breast cancer risk were selected for further analysis.  Specifically, the 
presence of SNP variants and gene expression and promoter methylation levels of DNA-relevant 
genes were queried for an association with observed repair capacity and breast cancer case status 
(Figure 1).   
 
All studies were carried out among participants enrolled in the New York site of the Breast Cancer 
Family Registry, one of six sites established to further understanding of the genetic epidemiology of 
breast cancer.  Participants enrolled in the registry had to meet one or more of the following eligibility 
criteria: 1) A female relative who had been diagnosed with either breast or ovarian cancer prior to the 









Figure 1. Overall study hypothesis
The  undertaken studies focus on assessing the risk of breast cancer risk 




Two or more female relatives who had been diagnosed with breast or ovarian cancer after the age of 
45; 4) A male relative diagnosed with breast cancer at any age; 5)  A known carrier of BRCA1 or 2 
mutation.  Epidemiologic risk factors, family history of cancer and food frequency information were 
determined through questionnaires, which gathered information on demographics, ethnicity, history of 
all cancers, smoking, alcohol consumption, reproductive history, hormone use, height, weight, physical 
activity, and dietary intake.  Blood was collected at the time of recruitment, on average 5 years after 
diagnosis for cases
127
.   
We conducted familial based case-control studies, selecting sisters discordant for breast cancer among 
the families participating in the New York site of the registry.  For each study, we selected the subset of 
discordant sister-sets for whom relevant biospecimens were available (Figure 1). 
 
Hypothesis 1: Breast cancer cases are more likely to have deficient NER capacity than their unaffected 
sisters 
Figure 2. Overall study design
Each familial-based case control study was conducted among sisters discordant for disease with available 
biospecimens relevant for each study.
Families at high risk of breast 
and ovarian cancer 
N=1342
Sisters discordant for case 
status
N=850 (355 sets)
Sisters discordant for case 
status with available WBCs
N=850 (355 sets)
NER capacity study Genotyping study Gene Expression/Methylation
Studies
LCL   =  Lymphoblastoidcell 
lines
WBC =  White Blood Cells
MN    =  Mononuclear Cells
Sisters discordant for case 
status with available MN cells
N=569 (218 sets)
Sisters discordant for case 




Specific Aim 1a:  Develop a competitive ELISA applicable in a population-wide setting with sufficient 
sensitivity and specificity to evaluate inter-individual differences in NER capacity using nuclear extracts 
derived from relatively NER proficient and deficient lymphoblastoid cell lines 
Specific Aim 1b:  Apply the developed ELISA method to compare repair distribution between cases and 
controls using nuclear extracts of lymphoblastoid cell lines derived from sisters discordant for breast 
cancer (N=266) who are participants in the Breast Cancer Family Registry, most of whom were 
previously assayed for NER capacity using an immunohistochemical method 
Hypothesis 2: Breast cancer cases are more likely to present with variants in DNA repair-relevant 
genes than their unaffected sisters. 
Specific Aim 2a:  Assess single nucleotide polymorphisms in DNA repair-relevant genes and determine 
the association with case-status 
Specific Aim 2b:  Assess the impact of extended family history on the association between the 
presence of variants in DNA repair-relevant genes and breast cancer risk 
Hypothesis 3:  Breast cancer cases are more likely to have reduced expression levels of DNA repair-
relevant genes than their unaffected sisters 
Specific Aim 3a:  Assess expression levels of DNA repair-relevant genes and determine the 
association with case-status 
Specific Aim 3b:  Assess the impact of extended family history on the association between the 
expression levels of in DNA repair-relevant genes and breast cancer risk 
Hypothesis 4:  Breast cancer cases are more likely to have increased promoter methylation levels in 
DNA repair-relevant genes than their unaffected sisters 
Specific Aim 4a:   Assess promoter methylation levels of DNA repair-relevant genes and determine the 
association with case-status 
Specific Aim 4b: Determine the correlation between promoter methylation levels and gene expression 
levels of DNA repair-relevant genes for which information is available for both in the sister-sets 
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Chapter II. Phenotypic assessment of NER capacity  
Abstract 
 
Several studies have indicated an association between suboptimal NER capacity and breast cancer 
risk.  While these findings have implications for early detection, validating these initial studies and 
developing a potential screening tool assessing NER capacity in a population-wide setting is limited by 
the technology available to measure DNA repair.  Current phenotypic assays are labor intensive and 
not applicable for large scale population studies. To address this need, we have developed an NER 
capacity assay using a competitive ELISA-based method to determine the in vitro removal of 
benzo(a)pyrene diol epoxide (BPDE)-DNA adducts.  This method was subsequently applied in a family-
based case-control study among sisters recruited in the New York site of the Breast Cancer Family 
Registry (NY-BCFR) previously assessed for NER capacity using the immunohistochemical method.  
Unlike previous studies, the current study did not detect an association between NER activity and 
breast cancer risk (OR = 1.01, 95%CI=0.97,1.05).  The findings of the current study also do not 
correlate with the findings within the same population based on the immunohistochemical method (r=-
0.01, p=0.86).  
The previously suggested role of suboptimal NER capacity in breast cancer susceptibility and the 
discrepancy in findings among the various investigations highlight the need for additional studies to 
validate the implied association.  Furthermore, since currently available methodologies to assess 
overall NER capacity are not designed to be applied in a population-wide setting for the necessary 
validation or subsequent development as a screening tool, other avenues, potentially focused on more 









The NER pathway targets bulky, helix-distorting DNA lesions arising from environmental exposures 
including UV radiation and tobacco smoke
119
.  Studies investigating the impact of NER on cancer risk 
have mainly focused on skin and lung cancer as outcomes of interest since exposures known to induce 
NER-targeted lesions are also typically associated with these cancer sub-types
120
.  Though not as 
strongly associated, several studies have indicated that DNA damage arising from these types of 
exposures may also be relevant for breast cancer.  Of particular note, DNA adducts have been shown 
to present at higher levels in breast tissue derived from breast cancer cases compared to breast tissue 
derived from non-cancer controls
121,122
.  The adduct types observed in these studies are indicative of 
exposure to polycyclic aromatic hydrocarbons (PAH), a class of chemical carcinogens contained within 
cigarette smoke, incomplete combustion of fossil fuel, and charred meats
123
.   
The link between adduct levels and risk of breast carcinogenesis was further established in several in 
vitro studies.  Human breast epithelial cells treated with benzo(a)pyrene (B(a)P), a type of PAH, 
undergo changes in cell morphology, increased growth rate, and exhibit anchorage-independent 
growth and invasiveness in agar-methocel.  Subsequent inoculation of clones isolated from agar in 
SCID mice led to tumor formation, indicating the tumorogenic potential of the transformed cells
124
.   
This transformation process is triggered through the incorporation of incorrectly specified bases 
opposite helix-distorting lesions, such as DNA adducts, during replication.  Failure of the NER pathway 
to remove such lesions, especially if present in key genes related to cell cycle progression and 
proliferation, can lead to persistent mutations that trigger carcinogenesis
125
.  Hence, the observed link 
between breast cancer susceptibility and adduct persistence may be related to inherent deficiencies in 
NER capacity to repair damage resulting from environmental exposures. 
The ability to assess the relationship between NER and breast cancer susceptibility is limited by the 
technology available to detect inter-individual differences in repair.  One approach focuses on the 
genotypic level, querying for the presence of SNPs within regions in specific DNA repair genes.  While 
genotyping assays can be carried out in a high-throughput format, studies assessing the impact of DNA 
repair SNPs on breast cancer risk have identified few relevant SNPs thus far, often with borderline 
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associations.  Associations observed in studies utilizing phenotyping assays are generally much more 
robust than what is typically observed in SNP studies, likely due to the more comprehensive measure 
of pathway activity captured by such assays.   
A few studies have reported on the risk of breast cancer due to suboptimal NER capacity utilizing 
phenotyping assays.  In a retrospective case-control study conducted in Puerto Rico, a 36% reduction 
in NER capacity, as determined by the HCR assay, was observed among breast cancer cases 
compared to cancer-free controls
108
.   
Our own group has developed an assay to measure NER activity using an immunologic-based 
approach.  In a study conducted in sister-pairs discordant for breast cancer enrolled in the NY-BCFR, 
this method was implemented to demonstrate a significantly lower capacity to repair NER-specific 
damage among breast cancer cases compared to their control sisters, with a more than two-fold 
increase in risk among subjects with repair levels below the median of controls
109
.   
While findings based on both methodologies indicate that reduced NER capacity may be a potential 
risk factor for breast cancer, the small sample size and retrospective nature of these studies 
necessitate further inquiries in larger prospective cohorts to substantiate the results.  However, as both 
these methods are time-consuming and tedious to carry out, utilizing them in such settings would not 
be feasible.   
Additionally, given a true association between NER capacity and breast cancer risk, an assay capable 
of detecting such a risk factor would be instrumental as a potential screening tool.  Availability and 
implementation of such a tool could enable the reduction in breast cancer incidence by focusing 
prevention strategies to relevant populations and improving prognosis through early detection.   
However, the aforementioned characteristics of currently existing phenotyping assays would impede 
translating them for use within this desired context. 
In this study, we set out to develop a high-throughput competitive ELISA method capable of identifying 
susceptible individuals with suboptimal NER capacity, as indicated by the ability to remove PAH-
induced BPDE-DNA adducts
126
 (Figure 1).   Following optimization, we conducted a case-control study 
among sisters discordant for breast cancer case status, previously assayed for NER capacity using the 
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immunohistochemical method, using the newly developed competitive ELISA assay to further 














Figure 1. Formation of Benzo(a)pyrene diol epoxide
Carcinogenic effect associated with PAH exposure is mediated by Benzo(a)pyrene diol epoxide (BPDE), the 
intermediate by-product of B(a)P.  Metabolic activation occurs through a series of steps following the 
internalization of B(a)P, commencing with the initial epoxidation by cytochrome P450 enzymes to generate 
B(a)P-7,8-epoxide.  Epoxide hydrolase converts this intermediate into B(a)P-7,8 diol.  A second epoxidation




Materials and Methods 
Lymphoblastoid cell culture 
Lymphoblastoid cell lines were thawed from -140°C and spun down.  After removal of the DMSO-
containing freezing medium, 10% of the cells were re-suspended in fresh medium containing RPMI 
1640 (Fisher Scientific, Pittsburgh, PA), 1% Penicillin/Streptomyocin (Mediatech, Manassas, VA), and 
15% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and placed in a 37°C incubator.  
Samples were deemed ready for extraction once a confluence of at least 8x10
6
 cells was reached. 
Nuclear protein extraction 
Cells were spun down and re-suspended in 1mL PBS.  Nuclear protein was extracted from the cells 
using an NE-PER nuclear and cytoplasmic extraction kit (Fisher Scientific, Pittsburgh, PA).  Following 
extraction, the samples were buffer exchanged into NE buffer (10mM Tris-HCl, 200mM KCl, 1mM 
EDTA) using Zeba spin columns (Fisher Scientific, Pittsburgh, PA).  Protein concentration was 
determined using a Bradford Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA), with 
aliquots of samples diluted 1:8 in water read at 595nm absorbance against a bovine serum albumin 
(BSA) based standard curve ranging from 7.5ug/mL to 75ug/mL. All samples were aliquoted at a final 
concentration of 0.75ug/uL in 20% glycerol and stored at -80°C.   
BPDE modified-DNA substrate generation 
0.05mg/mL diolepoxide in ethanol was mixed with 1mg of calf-thymus DNA (0.5mg/mL TE) in a 1:2 
volume ratio.  The reaction was left to incubate in the dark at 37°C for 1 hr.  To remove any remaining 
unreacted BPDE derivatives, the modified DNA was extracted 5X using equal volumes of TE-saturated 
ethyl acetate (1 part TE:8 parts ethyl acetate).  Finally, the DNA was precipitated by adding 3M sodium 
acetate (pH 5.0) to a final concentration of 0.3M and 3 volumes 100% ethanol.  Precipitation was 
repeated until the A350/A260 ratio reached equilibrium.  The concentration of the total DNA amount 
extracted was calculated using the following formula:  
[DNA, umol/ul]=(A260-0.2(A350))/coeff ext A260 




[BP-G, umol/ul]=A350/coeff ext. A350 
The percent modification of the generated substrate ([BP-G]/[DNA]*100) was determined to be 0.95%. 
BPDE adduct removal activity assay 
Each repair reaction mixture consisted of 200ng nuclear extract and 250fmol sonicated BPDE modified 
DNA in a 100uL volume of NE buffer.  Following a 1hr incubation at 37°C, the reaction mixtures, as well 
as a set of standard curve dilutions in the range of 0-250fmols of sonicated BPDE-modified DNA, were 
heat denatured at 95°C for 15min and then cooled on ice.   
BPDE-adduct removal competitive ELISA 
The wells of UV transparent flat bottom plates (Corning, Tewksbury, MA) were coated with 5ng BPDE-
DNA/50ul PBS/well. The plates were dried down in an overnight incubation at 37°C and stored the 
following day at -20°C until time of assay. 
Prior to use, plates were thawed to room temperature and rinsed with wash buffer (1X PBS, 0.05% 
Tween, 0.2% NaN3) using an ELx405 washer (BioTek, Winooski, VT).  The plates were then blocked 
using blocking buffer (1X PBS, 0.05% Tween, 1% fetal calf serum (FCS)) at 200uL/well and incubated 
at 37°C for 1 hr.  During this blocking period, the extract repair reactions were set up.  A 1:1000 dilution 
of the in-house generated monoclonal antibody 5D11 was prepared and added to the inactivated 
reaction mixtures and standard curve in a 1:1 ratio for a final 1:2000 antibody concentration. Following 
the blocking incubation and washing of the plates, the samples, in the presence of 5D11, were added 
to the plates in duplicate at 100uL/well.  Following a 1.5 hr incubation at 37°C, the plates were washed 
and secondary goat anti-mouse IgG alkaline phosphatase (Sigma-Aldrich, St. Louis, MO) was added in 
a 1:1000 dilution in blocking buffer at 100uL/well.  Following a subsequent 1.5 hour incubation at 37°C, 
the plates were washed and rinsed with 1% diethanolamine.  p-nitrophenyl phosphate substrate was 
added to the plates at 100uL/well.  After a final incubation at 37°C for 60min, the plates were read at 
450nm using a SpectraMax Plus UV spectrophotometer (Molecular Devices, Sunnyvale, CA).  The 
amount of BPDE-adduct remaining in the wells following the repair reaction was quantitated by 
referencing the optical density (OD) values from the samples against the values generated by the 
standard curve.   Each plate was set up to include duplicates of each sample, zero-antibody 
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background control wells to which only NE Buffer was added, and an internal control sample run on 
each plate to monitor for batch effects.  Five percent of the samples were repeated during each run to 
assess intra-assay variability. 
Study subjects 
Subjects consisted of 114 sister-sets (N=246) discordant for breast cancer enrolled in the NY-BCFR 
previously assayed for NER capacity using the immunohistochemical method (Figure 2). 
 
Statistical analysis 
Chi-Square tests were performed to compare distributions of demographic variables between cases 
and controls.  Linear regression was conducted to assess the impact of known breast cancer risk 
factors on adduct removal capacity.  Student’s t-test was performed to compare mean case-control 
differences in BPDE-DNA removal capacity.  Conditional logistic regression analysis was conducted, 
Figure 2. NER capacity study design
The study was conducted among sisters discordant for disease with 
nuclear extracts available from LCLs.
Families at high risk of breast 
and ovarian cancer 
N=1342
Sisters discordant for case 
status
N=850 (355 sets)
Sisters discordant for case 







adjusting for age at blood draw and smoking status, and odds ratios were calculated using maximum 
likelihood methods.  Adduct removal capacity was analyzed as a continuous variable, with change in 
risk assessed due to 1% decrease in adduct removal capacity, as well as a categorical variable, with 
cut-offs based on tertiles within unaffected sisters.  Spearman correlation was calculated to determine 
the concordance between findings based on the competitive ELISA and immunohistochemical 
methods.  All tests were performed using R: A Language and Environment for Statistical Computing, R 




















Principles of the competitive ELISA-based method to determine the in vitro removal of BPDE-
induced DNA adducts 
The paradigm of the developed assay rests on detecting the enzymatic activity of the host’s repair 
machinery in the presence of its target substrate.  The development of the methodology involves 
optimizations on two fronts: a) mimicking the in vivo presentation of damage to induce a response by 
the NER machinery and b) detecting the level of the subsequent response.  To induce NER activity, 
BPDE- DNA adducts are exposed to nuclear proteins containing the relevant repair enzymes.  
Differences in the levels of adduct removal, indicative of repair capacity, is then determined through a 
competitive ELISA.  During this detection phase, 5D11, a BPDE- DNA adduct specific antibody 
previously established by our group, is added to a BPDE-DNA adduct coated micro-titer plate in the 
presence of the deactivated repair reaction mixture.  In this context, unrepaired BPDE-DNA adducts 
remaining in the reaction mixture compete with BPDE-DNA adducts bound to the micro-titer plate 
antibody binding.  Successful micro-titer plate antibody binding can then be captured by the 
subsequent tethering of conjugated secondary antibody through the interaction with its alkaline 
phosphatase substrate, resulting in a colorimetric reaction.  Referenced against wells in which the 
reaction mixture contains no extract or competitor, high antibody detection indicates less inhibition by 
the competitor BPDE-DNA adduct present in the reaction mixture, which in turn, indicates high BPDE-
adduct removal activity in the presence of nuclear extract. Running a standard curve of BPDE-DNA 
adduct competitor alongside the reactions during the ELISA provides a means to quantify level of 
adduct removal capacity.  Using the standard curve, the amount of adduct level present in the wells 
following the reaction can be calculated based on the level of observed antibody binding.  Given the 
known input amount of BPDE-DNA adduct substrate added to each reaction, the level of adduct 
removal, indicative of NER capacity, can be determined (Figure 3). 
Development of protocol 
The initial set of experiments focus on optimizing the assay conditions.  Setting up the ELISA detection 





fmol OD1 OD2 Average -
Blank
%Binding
0 0.69 0.72 0.60 100
50 0.62 0.59 0.50 83.4
100 0.50 0.54 0.42 69.2
150 0.41 0.42 0.31 52.2
200 0.35 0.36 0.25 42.1
250 0.28 0.28 0.18 29.1
ID OD1 OD2 Average-
Blank
% Binding Adduct  
remaining (fmol)
% adduct removed 
1 0.463 0.450 0.357 59.3 135.0 46.0
















Figure 3.  Principles of NER-ELISA assay
(a) Following incubation between nuclear extracts and BPDE-DNA adduct substrate, the heat-inactivated 
reaction is mixed with 5D11 monoclonal antibody and added to a BPDE-DNA adduct coated micro-titer 
plate.  Unrepaired substrate DNA in solution acts as a competitor for antibody binding to the bottom of the 
plate.  Percentage binding is subsequently determined through an alkaline phosphatase conjugated 
secondary antibody detection system.   (b) Percent binding is calculated based on optical density readings 
of wells containing reaction mixtures referenced against maximum antibody binding no -extract control 
wells.  BPDE-DNA adduct competitior standard curve  can then be used to convert these values into 
quantities of adduct substrate remaining in the wells following the reaction.  Finally, % adduct removed, 
can be determined based on the original input amount of adduct substrate added to the reaction.  Example 
adduct removal calculations for two extracts (ID 1 and 2), based on an original reaction input of 250fmol 




coating and the primary BPDE-DNA adduct specific 5D11 monoclonal antibody amounts which will 
result in an acceptable OD absorbance reading range within a feasible amount of development time.   
When testing varying levels of the BPDE-DNA adduct competitor, the linear range of inhibition due to 
the substrate ranged between concentrations of 50-250fmoles (Figure 4).   
Linear levels of inhibition were observed at all tested levels of BPDE-DNA adduct coating (Figure 5).   
While linearity was also maintained at varying levels of 5D11 monoclonal antibody titrations, there was 
a distinct positive shift in percent inhibition at the lowest dilution of 5D11 (Figure 6).  However, for every 
decrease in antibody titration dilution, there was a concomitant increase in the time required for 
colorimetric detection.    
Hence, an antibody dilution of 1:2000, the lowest dilution allowing for a reasonable window of 
colorimetric development, was selected.  Finally, sufficient time for the development of the colorimetric 
reaction was determined by examining a series of optical density readings following the termination of 
the assay.  Readings typically reached consistency within one hour of the commencement of the 
colorimetric reaction (Figure 7).   
Based on this series of titration experiments, the competitive ELISA conditions were set at 5ng BPDE-
DNA adduct coating, 250fmol BPDE-DNA adduct substrate, a 1:2000 dilution of 5D11 primary 
monoclonal antibody, and a colorimetric reaction time of 1hr. 
Repair reaction conditions that needed to be determined include repair reaction time, repair reaction 
temperature, nuclear extract amount, and buffer components of the reaction mixture.  For this set of 
experiments, a single batch of nuclear proteins was extracted from the commercially-purchased 
lymphoblastoid cell line of an apparently normal individual (Coriell Cell Repositories, Camden, NJ) to 
test the repair reaction parameters of interest.  The competitive ELISA for the detection of adduct 
removal following all repair reaction experiments was conducted according to the previously outlined 
established protocol.   
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Adequate repair reaction time was determined through a time course analysis.  Increasing adduct 
removal was observed with increasing reaction time, with an eventual plateau reached after 4hrs.  As 
the relationship was most linear within the one-hour time-frame, this reaction time was used for all     
                                                                                                                                                                             
Figure 4.  Generated BPDE-adduct DNA substrate acts as inhibitor in 
competitive ELISA assay
(a)  Degree of inhibition observed due to varying concentrations of BPDE-
DNA adduct competitor substrate (b) Range of BPDE-DNA adduct substrate 





further experiments (Figure 8). The appropriate nuclear extract amount was determined by conducting 
a concentration curve.  As expected, increasing amounts of extract afforded greater BPDE-DNA adduct 
removal.  While the presence of the highest tested levels of extract lead to the highest observed 





Figure 5.  Linearity of substrate inhibition at varying levels of BPDE-DNA adduct coating 
Linearity was maintained across all shown levels of BPDE BPDE-DNA adduct coating. All other 
components of the competitive ELISA were as described.
Figure 6.  Impact on BPDE-DNA adduct substrate inhibition due to 5D11 monoclonal antibody 
titration 
All BPDE-DNA adduct substrate standard curves were generated using microtiter plates coated with 




         
 
 
experiments as this amount lead to the most consistent measurements (Figure 9). 
Slight variations in repair activity were also observed by varying repair reaction temperatures.  The 
highest levels of adduct removal were observed between a temperature range of 25°C and 37°C 
(Figure 10).  The latter was selected for further experiments, as this temperature most closely reflects 
in vivo conditions.  Additional in vivo conditions that would have to be met in order to recover the 
cellular NER activity of the isolated nuclear proteins includes the potential presence of cofactors that 
may aid in the activation of components in the NER pathway.  To test whether this is in fact the case, a 
set of repair reactions was carried out, one in a reaction mixture buffered according to conditions 
previously established as appropriate for assays determining nuclear protein activity (NE buffer) and 
the other in the physiological standard phosphate buffered saline (PBS).  As can be seen in Figure 11, 
Figure 7.  Stability of optical density readings reached over time
Standard curve of BPDE-DNA adduct substrate at 1/2000 antibody titration and 5ng BPDE DNA 
coating.  All other elements of the competitive ELISA were as previously described.
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buffer constituents do impact adduct removal capacity of the nuclear proteins.  Observed adduct 
removal activity was indeed higher in NE buffer as compared to PBS. 
 
 
Figure 8. Time course analysis of extract activity
200ng aliquots of nuclear extracts from the lymphoblastoid cell line of an 
apparently healthy individual were prepared and incubated with 250fm  
BPDE-DNA substrates for the differing indicated time-spans.  All samples 
were then run using the competitive ELISA method as previously described.
a) BPDE removal capacity measured across a four-hour time course






Figure 9.  Percent adduct removal increases with  increasing amounts of nuclear extract 
Indicated concentrations of nuclear extract were incubated with 250fmol BPDE-DNA adduct substrate for one 
hour.  Following the reaction, the competitive ELISA was carried out using established conditions .
Figure 10. Nuclear extract activity varies across repair reaction temperatures
Four parallel sets of reactions were set up with 200ng nuclear extracts and 250fmol BPDE-DNA adduct substrate 




Once the optimized conditions were determined and set, the working parameters of the assay, 
including specificity, range of detection and inherent variability of the assay were assessed. 
The specificity of nuclear extract activity was tested by examining the impact on adduct removal 
capacity upon deactivating proteins present in the reaction mixture.  For this purpose, a set of 
experiments was conducted in which a normal repair reaction was run alongside a reaction in which 
proteinase K, an agent that degrades protein, was introduced at the commencement of the reaction.  In 
the presence proteinase K, adduct removal capacity is indeed knocked down compared to the 
uninhibited repair reaction (Figure 12).  This indicates that the observed reduction in adduct levels 
following a repair reaction is largely due to the presence of active nuclear proteins.  
Figure 11. Buffer components impact level of adduct removal activity during repair reaction
Two repair reactions were set up in parallel, each with 200ng nuclear extracts and 250fmol BPDE-
DNA adduct substrate but differing in buffer constituents.  Higher levels of activity were consistently 
observed in reaction mixtures containing NE buffer, a buffer which has been previously described for 





Finally, the ability of the assay to distinguish between proficient and deficient NER activity was 
assessed in a set of experiments utilizing extracts derived from commercially-purchased (Coriell Cell 
Repositories, Camden, NJ) lymphoblastoid cell lines from an apparently normal individual, an XP 
individual deficient in XPC and an XP individual deficient in XPD.  The parallel repair reactions and 
competitive ELISA experiments were carried out according to the outlined established conditions.  As 
hypothesized, the assay indicated a knock-down in adduct removal capacity among both XP individuals 
compared to adduct removal observed in the apparently normal individual (Figure 13).  
The inherent variability of the ELISA was determined by comparing the adduct removal capacity of the 
same extract run in separate independent experiments.  The calculated coefficient of variation of 12.3% 
among the four identically conducted trials (data not shown) falls within an acceptable range of inter-
assay variation commonly reported for ELISAs. 
Figure 12. Active nuclear proteins are required for adduct removal activity
Two repair reactions were set up in parallel with 200ng nuclear extracts and 250fmol BPDE-DNA 
adduct substrate.  Proteinase k (100ng/uL) was  added to one of the two reactions at the 




Distribution of adduct removal capacity in a group of healthy individuals 
The effect of several factors known to impact DNA repair capacity was evaluated among 122 
unaffected women enrolled in the NY-BCFR.  Adduct removal capacity among these women ranged 
from 9.85-53.9%.  The mean adduct removal capacity of 34.0% with standard deviation of 8.5% is in 
line with the previously reported adduct removal capacity among these women based on the 
immunohistochemical assay (35.1% +/- 24.4%)
109
 (Figure 14). 
None of the selected variables were observed to significantly impact adduct removal capacity within the 
unaffected women.  However, several borderline associations were observed in the expected direction.  
As seen in Table 2, women above the median age at menopause had reduced adduct removal 
capacity compared to women below the median age at menopause (p=0.05).  Similarly, women with an 
extended family history of breast cancer had reduced adduct removal capacity compared to women 
without an extended family history (p=0.07).     
Figure 13. Assay range of adduct removal detection
Three parallel repair reactions were set up with 250fmol BPDE-DNA adduct substrate.  Nuclear 
extracts for each reaction were derived from lymphoblastoid cell lines of an apparently normal 





To determine whether case-control differences in NER activity could be observed using the competitive 
ELISA method, we assessed the adduct removal capacity from nuclear extracts derived from the LCLs 
of sisters previously analyzed using the immunohistochemical method in a family-based case control 
study.   
  
The range in adduct removal capacity observed among cases spanned from 13.22% to 54.42% with a 
mean and standard deviation of 33.98% and 8.45%, respectively.   The difference in mean adduct 
removal capacity between cases and controls was not statistically significant (p=0.98) (Table 3).  
Conditional logistic regression analysis also did not indicate a significant association adduct removal 
capacity and breast cancer risk, adjusted for age at blood draw and smoking status (Table 4).  
Furthermore, NER capacity measured within sister-sets as indicated by the NER-ELISA method did not 
Figure 14. Distribution of adduct removal capacity among the unaffected sisters
44 
 
correlate (r=-0.01, p=0.86) with the NER capacity previously determined within the same group using 
the immunohistochemical method (Figure 15). 
 
 
Estimate St.Err t-value Pr(>|t|
Age                          
(>50 vs ≤50) -3.02 1.52 -1.99 0.05
Smoke              
(Ever vs. Never) -2.52 1.53 -1.65 0.10
BMI (kg/m2)                           
(≥25 vs <25) -0.20 1.54 -0.13 0.90
Family History     
(>1 vs. ≤1) -2.80 1.55 -1.81 0.07
Table 1. Association between selected variables and 
adduct removal capacity among unaffected sisters
Variable No. cases (%) No. controls (%) p-valueα
(n=121) (n=124)
         ≤50 65   (53.3) 0.65
         >50 57   (46.7)
BRCA1 (+) mutation 10     (8.3) 6     (4.8) 0.41
BRCA2 (+) mutation 3       (2.5) 2     (1.6) 0.98
Ethnicity
         Non-hispanic White 93     (77.5) 90   (72.6) 0.67
         African American 1       (0.80) 1     (0.80)
         Other 26     (21.7) 33   (26.6)
Smoking Status
        Never 68   (53.8) 0.93
        Ever 53     (43.8) 56   (45.2)
BMI (kg/m2)
         <25 62   (52.1) 60   (48.4) 0.65
         ≥25 57   (47.9) 64   (51.6)
         =1 71   (58.7) 75   (60.5) 0.87
         >1 50   (41.3) 49   (39.5)
α Pearson's Χ2 test
Table 2. Distribution of selected variables among sisters affected and 
unaffected with breast cancer 
68     (56.2)
Family History                    
Age at blood draw             
69     (57.0)









N Mean N Mean
All 120 34.0 ± 8.39 123 34.0 ± 8.52 0.98
         ≤50 68 34.5 ± 8.54 66 35.4 ± 8.49 0.56
         >50 51 33.3 ± 8.20 56 32.4 ± 8.33 0.54
         pδ 0.44 0.05
Smoke Status
        Never 67 34.7 ± 8.03 67 35.1 ± 8.61 0.76
        Ever 52 33.2 ± 8.82 55 32.6 ± 8.27 0.74
         pδ 0.32 0.10
BMI (kg/m2)
<25 61 32.9 ± 8.05 59 34.1 ± 9.61 0.46
≥25 57 35.3 ± 8.63 63 33.9 ± 7.43 0.32
         pδ 0.11 0.90
Family History
=1 70 34.3 ± 9.45 74 35.1 ± 8.13 0.60
>1 49 33.6 ± 6.65 48 32.3 ± 8.90 0.42
         pδ 0.62 0.07
δ P-value determined based on Student's t-test
Cases Controls
Age at blood draw             
Table 3. Adduct removal capacity among sisters affected and unaffected 
with breast cancer 
Variable
Odds Ratio         
(95% CI)
Adjusted Odds Ratio     
(95% CI)*
Adduct Removal Capacity (%)
Continuous 0.99   (0.95,1.04) 1.0     (0.95,1.04)
Tertile 1: (≤28.0) 0.85   (0.39,1.87) 0.87   (0.39,1.97)
Tertile 2: (28.0-39.6) 0.89   (0.33,2.36) 0.91   (0.33,2.46)
Tertile 3: (>39.6) 1.0     (referent) 1.0      (referent)
*Model adjusted for age at blood draw and smoking status
Table 4. Conditional logistic regression analysis of the relationship between 















Figure 15. Correlation between immunohistochemical and ELISA assessments of adduct 
removal capacity among analyzed sister-sets





The current study was undertaken to develop a high-throughput DNA repair phenotyping methodology 
for potential implementation as a screening tool within a population-wide setting.  While several 
phenotyping assays are currently available, constraints on scalability have limited the application of 
these assays to describe repair capacity-associated implications for cancer risk within small population 
subsets.  
Two such methodologies include HCR and the in vitro BPDE-DNA adduct removal capacity.  While 
studies have suggested associations between NER capacity and breast cancer risk utilizing these 
assays, both require a series of time-consuming and cumbersome steps, a common issue with 
phenotyping in general.      
In addition to the multi-day time-frame entailed for the combined processes of repair reaction and 
detection, phenotyping assays are often carried out within living cell systems, adding a period of cell 
culturing until exponential growth is reached prior to the actual commencement of the repair reaction.  
This presents an additional challenge for matched case-control studies where concern over potential 
batch effects necessitates cell lines within the same set to be run together, further limiting the flexibility 
of the assay by requiring entire matched sets to reach exponential growth.  Lastly, reliable 
quantification of repair capacity is also an issue of concern for these assays.   The reliance on 
subjective assessments based on relative fluorescent or luminescent intensity only allows for crude 
measurements of repair capacity that are non-standardized and liable to bias. 
The development of the competitive NER ELISA addresses several of the challenges presented by 
currently available phenotyping assays.    In place of cultured cell lines, the repair reaction for the 
ELISA utilizes nuclear proteins.  As these cellular extracts can be isolated and stored as required, the 
investigator is afforded added flexibility in determining assay runs, rather than having the timing of the 
runs determined by the growth rate of the cell lines.  Scalability of the detection method is facilitated by 
the use of BPDE-induced damage specific 5D11, a monoclonal antibody previously isolated by our 
group and assessed to be sensitive enough to detect levels of damage that can be expected from 
carcinogen exposures typically observed within the population-based setting
128
. Unlike the BPDE-DNA 
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damage–specific polyclonal antiserum utilized in the immunohistochemical method, monoclonal 
antibodies can be reliably obtained from cultured cell-lines, and would allow for a theoretical limitless 
and consistent supply, facilitating scalability and reproducibility of the assay.  Finally, the 
implementation of a standard curve enables detection of absolute adduct levels, improving upon  the 
reliance on relative and subjective quantification of repair utilized by existing methods. 
While studies utilizing HCR and the in vitro BPDE adduct removal assay have both shown that 
suboptimal NER capacity impacts breast cancer risk, a similar association was not observed in the 
current study using the competitive ELISA method.  Several factors may explain the observed 
discrepancy in findings.   While the intended use of the assay will be to assess repair capacity within 
extracts derived from readily accessible primary mononuclear cells, the findings of the current study 
were based on assessing repair activity of LCLs.  These immortalized cell lines are able to evade 
senescence experienced by normal cells in culture and, therefore, provide the consistent supply of cells 
needed for assay development.  However, immortalization is achieved through Epstein Barr virus 
transformation of the cells, a process which may artificially alter cellular processes including DNA repair 
to an extent where they no longer truly reflect the original host functionality.   
While the study utilizing the immunohistochemical method also assessed NER capacity in LCLs, the 
ELISA method is distinguished by the further isolation of nuclear proteins from this cell source for the 
repair reaction.  The nuclear extracts, while affording additional flexibility to the assay, may also serve 
to increase the deviation from true in vivo conditions by focusing the assessment of protein activity 
within a context that is removed from potentially essential conditions and components present in the 
original setting in which repair activity takes place.  This artificial setting is in contrast to the entirety of 
the process captured in the viable cells of the immunohistochemical assay. 
The observed null findings may also be partially due to the introduction of measurement error.   A major 
potential for this type of bias can arise from the various opportunities to introduce batch effects into the 
assay, all of which may not be accounted for by post-hoc analysis.  The 247 cell lines were grown and 
extracted over a period of 1.5 years, and assessment of repair activity of the cell lines using the ELISA 
method commenced once nuclear proteins from all cell lines had been extracted.  As a result, a portion 
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of the cell lines had been stored frozen for close to 2 years at the time of assay, while others were 
stored for a relatively shorter period of time.  As protein activity degrades over time, it is possible that 
variations in protein activity measurements may be partially confounded by storage time.   However, 
since complete sister-set cell lines were grown simultaneously, difference in storage time within the 
same sets did not vary by more than a few days.  Still, as all lines stemming from the same set did not 
necessarily reach adequate cell density for extraction at the same time, extraction batch may have 
varied among individuals within the same sister-sets.  Finally, the ELISA assessment of repair capacity 
of the complete batch of cell lines was necessarily conducted over separate assay runs.  Potential 
variability between plates could introduce artificial variability between assayed samples.  Indeed, 
variation based on an internal control extract run alongside samples on every plate did indicate an 
inter-plate variability of 12%.  However, as sister-sets were run together on the same plate, variation 
due to this factor was accounted for. 
The inability to distinguish cases from controls based on NER capacity maybe due to limitations in the 
sensitivity and specificity of the assay.  Degradation of protein activity in the presence of proteinase K 
led to a knock-down but not a complete knock-out in observed activity.  Similarly, low levels of repair 
activity were observed in nuclear extracts derived from individuals with mutations in XPC and XPD.  
This noise, likely non-specific and unrelated to repair activity, limits the possible range of detection of 
the assay, as can be observed by the modest differences in repair capacity observed between extracts 
derived from an apparently normal individual compared to individuals with XP.  Given that these 
individuals represent the extreme ends of the spectrum of repair capacity detectable with this assay, 
the observed narrow range in values distinguishing these individuals may render the assay unable to 
distinguish more subtle differences in repair more typically observed within the population. 
The observed narrow range in detection is at least partially attributed to background noise of the assay.   
Repair activity, as determined by the ELISA, relies on the assumption that an increase in signal 
detected in the presence of nuclear extracts reflects a reduction in competitor level available to inhibit 
antibody binding to BPDE-DNA adduct coating.  However, the reduction in competitor availability could 
also potentially arise without actual repair-related removal of substrate adducts from the competitor 
pool.  An observed increase in BPDE-DNA adduct coating binding may arise in the presence of a 
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differential in antibody binding capacity between BPDE-DNA adduct coating and competitor.  For 
example, it is possible that during the reaction with nuclear extracts, components in the reaction 
mixture mask adducts in such a way that they are not recognized by the antibody, increasing the 
availability of the antibody to bind to the coating. 
Another assumption in the NER ELISA assessment of repair capacity is that BPDE-adduct removal 
capacity is reflective of overall NER activity.  In fact, in addition to ELISA-targeted damage recognition 
and damage removal, the completion of the pathway also encompasses insertion of the correct base 
and ligation to seal the nick.  It is, therefore, conceivable that the observed lack of an association 
actually reflects an underrepresentation of NER defects captured by the assay.  In addition to limiting 
the focus of repair capacity to substrate removal, the substrate specification can also introduce error in 
capturing true NER activity.   While BPDE-DNA adducts are major targets of the NER pathway, it has 
been shown that BER can also mediate these lesions
129
.  Hence, focusing on one specific lesion may 
prevent detecting deficiencies in NER capacity, as they may be masked by the complimentary activities 
of other pathways. 
The discrepant findings between the current and previous studies assessing the impact of NER 
capacity on breast cancer susceptibility highlight the complications involved in developing a 
phenotyping assay capable of capturing overall pathway activity.  Adequately mimicking in vivo 
conditions to effectively capture the intricacies of interacting components entails processes difficult to 
scale up into a high-throughput methodology, while the current attempt to simplify and standardize the 
required steps and components comes at the cost of adequately assessing repair activity.  Still, initial 
findings based on phenotyping have been informative in suggesting a role for NER capacity on breast 
cancer risk. Validating and translating these findings into a screening tool will require additional studies, 
likely ones focused on more specific endpoints within the pathway that are more amenable to be 






Chapter III: Mismatch repair polymorphisms as indicators of breast cancer risk 
Abstract 
Suboptimal DNA repair capacity is believed to contribute to genomic instability and, thereby, onset of 
carcinogenesis.  In fact, deficient repair has been reported to account for up to a five-fold increase in 
breast cancer risk.  Major cancer susceptibility genes involved in repair, including BRCA1 and BRCA2 
among breast cancer cases, have been identified.  However, mutations in these genes are thought to 
account for only 5-10% of familial cases.  Additional genetic susceptibility factors may play a role in the 
remaining cases, including polymorphisms in DNA repair pathway genes.  MSI, a commonly observed 
marker of MMR defects, has been observed in skin samples from breast cancer patients, suggesting a 
putative role for MMR in breast cancer.  In this study, we investigated polymorphisms in mismatch 
repair genes and their association with breast cancer risk among participants of the New York site of 
the BCFR (N=744).  Of the 313 sister-sets included in the registry, 306 sister-sets consisted of sisters 
discordant for disease.  A total of twelve SNPs were chosen and assayed using Taqman SNP 
genotyping kits from Applied Biosystems.  Using conditional logistic regression analysis, an association 
with breast cancer risk was observed for three of the twelve SNPs assayed.  A significant increase in 
breast cancer risk was observed due to the MutY_rs3219489 variant allele (OR = 2.24, 95% CI =1.11-
4.52) while a borderline increase in risk was observed due to the MSH2_rs2303428 variant allele (OR = 
1.71, 95% CI = 0.99-2.95).  A protective effect was observed due to the MLH3_rs175080 variant allele 
among women without an extended family history of breast cancer.  Future studies will focus on 













Breast cancer is one of the leading causes of cancer death among women, second only to lung 
cancer
143
.  Two influential susceptibility genes, BRCA1 and BRCA2, have been identified.  These 
genes encode proteins involved in facilitating DSBR, suggesting a critical role imparted by these genes 
on the maintenance of genomic integrity
159
.  Carriers of mutations in these genes have up to an 85% 
risk of developing breast cancer by the age of 70
18
.  However due to the associated lethality, complete 
loss of function in these genes is rare, accounting for only 5-10% of all observed cases.  Additional 
coverage of risk may be captured by less dramatic alterations, including SNPs. 
While DSBR-targeted damage, such as chromosomal aberrations, constitute the type of genomic 
instability most frequently associated with breast cancer risk, susceptibility to substrates targeted by 
other repair pathways may also confer risk.  In addition to DSBR, BRCA1 is also associated with a 
genome surveillance complex that includes MMR proteins to sensor and repair replication-associated 
DNA damage that have escaped the DNA polymerase proof-reading mechanism
160
.  These types of 
damage include point mutations that result from single base mismatches following the incorrect 
incorporation of a nucleotide, as well as frame-shift mutations that occur through errors in the number 
of bases incorporated at repetitive sequences, resulting IDLs. 
Such slippages are prone to occur in regions containing microsatellites, simple repeat sequences 
scattered throughout the genome.  Hence, detection of an alteration in the number of repeats, is a 
common marker used to identify a defect in MMR
161
.  
It has been proposed that such MSI-generating defects may be an early event in carcinogenesis that 
confer a mutator phenotype by inducing genomic instability, thereby enabling the acquisition of 
additional mutations necessary for tumor progression
162
.  Studies have already shown increased MSI 
within tumors, including breast, compared to normal tissues derived from the same individual, 
implicating defective MMR with breast cancer
115,163
.  Furthermore, in a study including 30 breast cancer 
patients, all cases with point mutations in either MLH1 or MSH2, two MMR genes, exhibited increased 
MSI in tumor versus control tissue, indicating that such sequence variations in MMR genes may play a 





To further investigate this potential relationship, we carried out a family-based case-control study 
among sisters discordant for breast cancer enrolled in the New York site of the BCFR to assess the 































Materials and Methods 
Study population 
The subjects for the current study included 313 sister-sets (n=714) consisting of sisters discordant for 
breast cancer enrolled in the New York site of the BCFR with available WBCs (Figure 1).   
 
Laboratory methods 
DNA was extracted from WBCs using a commercially available kit following the manufacturer’s 
instructions (Flexigene, Qiagen).  DNA concentration and quality was determined using a NanoDrop 
ND-1000 spectrophotometer with absorbance detection at 260nm and 280nm.     
Real-time PCR was carried out in 5uL reactions containing 5ng genomic DNA, 1X  
Taqman SNP Genotyping Assay Mix, and 1X Taqman Universal PCR Mastermix, containing DNA 
polymerase, dNTPs, and optimized buffer components. The PCR thermocycling protocol consisted of 
Figure 1. Genotyping study design
The study was conducted among sisters discordant for disease 
with DNA available from WBCs.
Families at high risk of breast 
and ovarian cancer 
N=1342
Sisters discordant for case 
status
N=850 (355 sets)
Sisters discordant for case 







95°C for 10min, followed by 45 cycles of 95°C for 15sec and 60°C for 90sec.  Assays were conducted 
in a 7900 Real-time PCR platform (ABI Applied Biosystems, Foster City, CA), and allelic discrimination 
was determined using software provided by the manufacturer.  Each plate contained non-template 
controls and 10% of the samples were re-assayed to determine concordance.  All laboratory personnel 
involved in sample handling were blinded to case status.  
SNP selection: 12 SNPs within genes of the MMR pathway were chosen for analysis.  Included SNPs 
met the following criteria: a) Association with cancer risk reported in epidemiologic studies; b) Minimum 
5% minor allele frequency in Caucasians; or c) Missense mutation incurred by presence of 
polymorphism in the coding region with minimum 1% minor allele frequency in Caucasians.  
Statistical analysis 
Hardy-Weinberg equilibrium was tested to assess deviations of observed from expected genotype 
frequencies among cases and controls.  Pearson’s chi-square tests were conducted to assess case-
control differences based on demographic variables.  These variables included age at blood draw, 




, cut-off based on WHO definition of 
normal range), age at menarchy (>13
 
vs ≤13 years, based on median age at menarche among 
unaffected sisters), age at first parity (>30
 
vs ≤30 years, nulliparous women were assigned age at blood 
draw), and extended family history (>1
 
vs 1).  Univariate conditional logistic regression was used to 
determine odds ratios and 95% confidence intervals associating individual queried genotypes with 
breast cancer risk.  Due to the low frequency of homozygous carriers of the variant allele for some of 
the SNPs assayed, the analysis for each SNP was also conducted upon combining heterozygous and 
homozygous carriers of the variant allele.  A final conditional logistic analysis was conducted to assess 
the combined effect of the two most strongly associated genotypes from the univariate analysis.  These 
findings were also adjusted for age at blood draw and smoking status.  A stratified conditional logistic 
regression analysis was also conducted to assess the presence of effect modification due to age (≤50 
vs. >50) and extended family history (>1
 
vs 1).  All analysis was performed using R: A Language and 





The SNPs chosen for the current study are shown in Table 1.  Seven of the 12 assayed SNPs are 
located within exons in which the presence of the variant allele induces a non-synonymous amino acid 
alteration.  Two of the selected SNPs (MLH1_1800734 and MSH6_rs3136228) are located upstream of 
the transcription start site (TSS), and the remaining three SNPs are located in introns 
(MLH1_rs1799977, MSH2_rs2303428, and MSH3_rs863221). 
  
 
The demographics of the study population are shown in Table 2.  A significantly higher number of 
BRCA1 mutation carriers were cases compared to controls.  No other case-control differences were 
observed.  




MLH1 rs1799977 NM_000249.2 715A>C         [I219V] C_1219076_20
MLH1 rs1800734 NM_000249.3 106G>A C__7535141_1_
MLH1 rs2286940 NG_007109.1 40128C>T C__16181046_10
MLH3 rs175080 NM_001040108.1 2531C>T       [P844L] C_1082805_10
MSH2 rs2303428 NG_007110.1 78238T>C     [IVS12-6T>C] C__11804019_1_
MSH3 rs26279 NM_002439.3 3133G>A       [T1048A] C_800002_1_
MSH3 rs184967 NM_002439.2 2846G>A       [R952Q] C_907914_10
MSH3 rs863221 NG_007109.1 40128C>T C___3103297_10
MSH4 rs5745325 NM_002440.2 289G>A         [A97T] C_3286081_30
MSH4 rs5745549 NM_002440.2 2741G>A       [N914S] C_1184803_10
MSH6 rs3136228 NG_007111.1 4531T>G C__28985526_10
MutY rs3219489 NM_001128425.1 1014G>C      [H335Q] C_27504565_10





A representative example of the amplification and allelic discrimination profile and plot for a set of 
samples genotyped for MutY_rs3219489 is shown in Figure 2.  As observed in the depicted run, a call 
rate of greater than 95% was observed for all assays. 
Variable No. cases (%) No. controls (%) p-valueα
(n=336) (n=408)
         ≤50 263   (64.5) 0.35
         >50 144   (35.3)
BRCA1 (+) mutation 24     (7.14) 14     (3.43) 0.03
BRCA2 (+) mutation 15     (4.46) 13     (3.19) 0.47
Ethnicity
         Non-hispanic White 210    (63.1) 235    (57.6) 0.30
         African American 6         (1.8) 10      (2.5)
         Other 117    (35.1) 163    (40.0)
Smoking Status
        Never 233   (57.1) 0.61
        Ever 137   (40.8) 175   (42.9)
BMI (kg/m2)
         <25 171   (51.0) 217   (53.8) 0.49
         ≥25 164   (49.0) 186   (46.2)
         <13 153   (46.0) 185   (42.6) 0.98
         ≥13 181   (54.0) 222   (57.4)
Parity
               Nulliparous 77     (23.0) 84     (20.6) 0.50
     Parous 259  (77.0) 324   (79.4)
<30 196   (63.2) 261   (67.4) 0.13
≥30 140   (36.8) 147   (32.6)
         =1 192   (57.1) 258   (63.2) 0.11
         >1 144   (42.9) 150   (36.8)
α Pearson's Χ2 test
Table 2. Distribution of selected variables among sisters affected and 
unaffected with breast cancer 
199   (59.2)
Age at menarche                    
(in years)
Age at first parity                   
Family History                    
Age at blood draw                  
(in years)
205   (61.0)







As seen in Table 3, several of the tested SNPs deviated significantly from Hardy-Weinberg (HW) 
equilibrium (MLH1_rs1799977, p=0.01, MLH1_rs2286940, p<0.01, MSH4_rs5745325, p=0.03).  This is 













Figure 2. Representative amplification plot (a) and allelic discrimination profile (b) and plot (c) of samples assayed for Muty_rs3219489 









random mating within the population.  As the current study is a family based case-control study, the 
allele frequencies may be skewed due to the presence of related individuals in the study population. 
Conditional logistic regression analysis revealed a significant association between the presence of the 
variant allele MutY_rs3219489 and breast cancer risk (OR=2.23, 95% CI = 1.10-4.52), upon adjusting 
for age at blood draw and smoking status.  Similarly, after adjusting for age at blood draw and smoking 
status, a borderline association was also observed for the presence of the variant allele 
MSH2_rs2303428 and breast cancer risk, upon combining homozygous carriers with heterozygous 
carriers (OR=1.71, 95% CI  =1.00-3.00) (Table 4). 
Including both MSH2_rs2303428 and MutY_rs3219489 in the same analysis, an increase in the odds 
of breast cancer was observed with increasing number of variant alleles in the two genes.  Individuals 
who are either heterozygous or homozygous carriers of the variant allele for both genes have a two-
fold increase in the odds of breast cancer over individuals with no variant allele for either gene, 
adjusted for age at blood draw and smoking status (Table 5). 
A stratified analysis was conducted to assess the presence of effect modification due to age and 




MLH1 rs1799977 6.12 0.01
MLH1 rs1800734 0.00 0.97
MLH1 rs2286940 14.7 <0.01
MLH3 rs175080 0.01 0.91
MSH2 rs2303428 1.03 0.31
MSH3 rs26279 0.02 0.89
MSH3 rs184967 0.09 0.76
MSH3 rs863221 4.00 0.05
MSH4 rs5745325 4.52 0.03
MSH4 rs5745549 1.22 0.27
MSH6 rs3136228 3.29 0.07
MutY rs3219489 0.89 0.34
Table 3. Test for Hardy Weinberg equilibrium of 









OR (95% CI) ORa (95% CI)
MLH1 rs1799977 AA                183  (55.3) 226   (55.8) 1.0     (Ref) 1.0     (Ref)
AG                118  (35.6) 143   (35.3) 1.05   (0.66-1.66) 1.07   (0.67-1.70)
GG                30    (9.1) 36     (8.9) 0.96   (0.45-2.06) 1.00  (0.46-2.14)
AG/GG 148  (44.7) 179   (44.2) 1.04   (0.66-1.64) 1.07   (0.67-1.69)
Freq(G) 0.27 0.27
rs1800734 GG                178  (53.6) 224    (55.2) 1.0      (Ref) 1.0      (Ref)
GA                131  (39.5) 154    (37.9) 1.00    (0.66-1.52) 0.99   (0.67-1.51)
AA                23    (6.9) 28      (6.9) 1.07    (0.50-2.31) 1.07    (0.49-2.32)
GA/AA 154  (46.4) 182    (44.8) 1.01    (0.67-1.52) 1.00    (0.66-1.51)
Freq(A) 0.27 0.26
rs2286940    CC                135   (40.7) 164    (40.4) 1.0      (Ref) 1.0      (Ref)
CT                133   (40.1) 168    (41.4) 0.96    (0.61-1.52) 0.97    (0.61-1.54)
TT                64     (19.3) 74      (18.2) 1.08    (0.58-2.00) 1.08    (0.58-2.00)
CT/TT 197   (59.4) 242    (59.6) 0.97    (0.62-1.53) 0.99    (0.63-1.56)
Freq(T) 0.39 0.39
MLH3 rs175080     GG                104    (31.9) 111     (27.4) 1.0      (Ref) 1.0      (Ref)
GA                158    (48.5) 207     (51.1) 0.68   (0.44-1.06) 0.69   (0.45-1.08)
AA                64      (19.6) 87       (21.5) 0.59   (0.32-1.08) 0.60   (0.33-1.10)
GA/AA 222    (68.1) 294     (72.6) 0.67   (0.43-1.03) 0.68   (0.44-1.05)
Freq(A) 0.44 0.47
MSH2 rs2303428    TT                242    (75.6) 310     (78.1) 1.0      (Ref) 1.0      (Ref)
TC                77      (24.1) 81       (20.4) 1.71    (0.99-2.95) 1.73    (1.00-3.00)
CC                1         (0.3) 6         (1.5)
TC/CC 78      (24.4) 87       (21.9) 1.71    (0.99-2.95) 1.73    (1.00-3.00)
Freq (C) 0.12 0.12           
MSH3 rs26279      AA                160    (48.2) 185     (46.1) 1.0       (Ref) 1.0       (Ref)
AG                143    (43.1) 171     (42.6) 0.85     (0.56-1.27) 0.84     (0.55-1.26)
GG                29      (8.7) 45       (11.2) 0.73     (0.38-1.42) 0.73     (0.37-1.42)
AG/GG 172    (51.8) 216     (53.8) 0.83     (0.56-1.25) 0.82     (0.55-1.24)
Freq(G) 0.30 0.33
rs184967     GG                236    (71.7) 285      (70.4) 1.0       (Ref) 1.0       (Ref)
GA                82      (24.9) 111      (27.4) 0.76    (0.49-1.19) 0.76    (0.49-1.19)
AA                11      (3.3) 9           (2.2) 1.34    (0.50-3.57) 1.34    (0.50-3.58)
GA/AA 93      (28.2) 120      (29.6) 0.80    (0.52-1.24) 0.80    (0.51-1.23)
Freq(A) 0.16 0.16
rs863221     TT                149    (44.5) 179      (44) 1.0      (Ref) 1.0      (Ref)
TG                155    (46.3) 194      (47.7) 0.89   (0.62-1.29) 0.88   (0.60-1.27)
GG                31      (9.3) 34        (8.4) 1.04   (0.51-2.10) 1.02   (0.50-2.07)
TG/GG 186   (55.6) 228      (56.1) 0.90   (0.63-1.30) 0.89   (0.62-1.28)
Freq(G) 0.32 0.32
MSH4 rs5745325    GG                163   (49.4) 199      (49) 1.0      (Ref) 1.0      (Ref)
GA                131   (39.7) 159      (39.2) 1.01   (0.67-1.53) 0.99   (0.65-1.50)
AA                36     (10.9) 48        (11.8) 0.94   (0.47-1.89) 0.89   (0.44-1.80)
GA/AA 167   (50.6) 207      (51) 1.0     (0.67-1.51) 0.98   (0.65-1.48)
Freq(A) 0.31 0.31
rs5745549    GG                292   (89.8) 363      (89.6) 1.0     (Ref) 1.0     (Ref)
GA                33     (10.2) 42        (10.4) 1.01   (0.50-2.05) 1.07   (0.53-2.18)
AA 0       (0) 0          (0)   
GA/AA 1.01   (0.50-2.05) 1.07   (0.53-2.18)
Freq(A) 0.05 0.05
MSH6 rs3136228    TT                164    (50.8) 191     (47.5) 1.0       (Ref) 1.0       (Ref)
TG                118    (36.5) 171     (42.5) 0.83    (0.53-1.31) 0.83    (0.53-1.32)
GG                41      (12.7) 40       (10) 1.44    (0.67-3.08) 1.44    (0.67-3.09)
TG/GG 159    (49.2) 211     (52.5) 0.88    (0.56-1.37) 0.88    (0.56-1.38)
Freq(G) 0.31 0.31
MutY rs3219489    CC                168   (50.8) 211     (52.4) 1.0      (Ref) 1.0      (Ref)
CG                127   (38.4) 162     (40.2) 1.05   (0.69-1.58) 1.02   (0.67-1.54)
GG                36     (10.9) 30       (7.4) 2.19   (1.08-4.44) 2.23   (1.10-4.52)
CG/GG 163   (49.3) 192     (47.6) 1.16   (0.78-1.73) 1.14   (0.76-1.70)
Freq(G) 0.30 0.28
a
 Adjusted for age at blood draw and smoking status
















OR (95% CI) ORa (95% CI)
MSH2_rs2303428 MutY_rs3219489
TT CC 125  (39.3) 170   (43.1) 1.0     (Ref) 1.0     (Ref)
TT CG_GG 114  (35.8) 138   (35.0) 1.20   (0.75-1.91) 1.19   (0.74-1.89)
TC_CC CC 35    (11.0) 39     (9.90) 1.65   (0.79-3.47) 1.70   (0.81-3.60)
TC_CC CG_GG 44    (13.8) 47     (11.9) 2.03   (1.04-3.95) 2.02   (1.03-3.94)
a
 Adjusted for age at blood draw and smoking status
Table 5. Association between combined MSH2 and MutY genotype and breast cancer risk
Figure 3. MLH3_rs175080 genotyping analysis stratified by extended family history




women without an extended family history of breast cancer, a protective effect due to the 
MLH3_rs175080 variant allele was observed (OR=0.28, 95% CI = 0.12-0.66) (Figure 3).  This 
protective effect was not observed among women with an extended family history of breast cancer 































In this study, an association was observed between the risk of breast cancer and the presence of two 
MMR-related SNPs, MSH2_rs2303428 and MutY_rs3219489. 
MSH2 is part of the MSHα heterodimer that initiates MMR upon recognition of post-replicative errors.  
This heterodimer consists of MSH2 complexed with either MSH6 to identify base mismatches and 
small IDLs or with MSH3 to identify larger IDLs.  Similarly, MutY is also involved in the recognition of 
mismatches, specifically the mispairing between adenine and 8-Oxoguanine.  The subsequent removal 
of the mispaired adenine by MutY followed by the correct replacement of the adenine with a cytosine 
allows the initiation of BER to remove the oxidized base and replace it with an intact guanine. As such, 
MutY is classified as a member of both MMR and BER.   
Deficiencies in MMR have most often been reported in association with the Lynch syndrome family of 
cancers, while no clear link between any type of cancer and reduced BER capacity has thus far been 
established.  Though few studies implicate either MMR or BER with breast cancer, one hospital based 
case-control study conducted in a Portuguese population has shown an association between SNPs in 
the MMR pathway and breast cancer risk
164
.  Similar to our study, a main effects finding associated the 
MLH3_rs175080 variant with a decrease in risk of breast cancer among women without an extended 
family history.  Contrary to our study, however, an increase in risk due to either MSH2_rs2303428 or 
MutY_rs3219489 variants was not observed in the study reported by Conde et al.  This is likely due to 
the inherent differences in the populations interrogated by the respective studies.  While our study 
selected high risk families, the Portuguese study focused on cases and unrelated controls without a 
family history of breast cancer. 
Although the variants identified in the current study have not been directly implicated with breast 
cancer, both MSH2_rs2303428 and MutY_rs3219489 have been associated with other cancer sub-
types.  MSH2_rs2303428 was shown to be associated with gastric cancer in a case-control study 
conducted within a Chinese population
165
.  Upon stratifying the study population, the observed effect 
was restricted to those with a family history of gastric cancer.  However, unlike our study, the strength 
of the association was elevated among those with onset of the disease prior to age 50.  Fewer studies 
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have implicated a role for MutY_rs3219489 in cancer.  However, it has most recently been associated 
with rectal cancer in a colorectal case-control study conducted in Sweden 
166
.   
While the MutY_rs3219489 SNP is located in exon 12 and results in a non-synonymous amino acid 
change, the MSH2_rs2303428 SNP is located in the intron region between exons 12 and 13. Based on 
computational analysis and functional assays, this polymorphism has been shown to be located near a 
splice acceptor site at the exon-intron boundary, and the presence of the variant leads to partial exon 
13 skipping, resulting in the translation of an altered protein from the alternatively spliced message
167
. 
Due to the low frequency of homozygous recessive individuals for the MSH2_rs2303428 SNP, we were 
not able to assess the risk of breast cancer due to the presence of two variant alleles.  However, the 
borderline association observed in the presence of one or more variant alleles suggests the presence 
of this allele functions through a dominant model.  Hence, the deleterious effect imparted by just one 
variant allele may also account for the low frequency of individuals with two copies of the variant.  
While an association with breast cancer risk was observed due to the presence of two 
MutY_rs3219489 variant alleles, the effect was lost upon combining heterozygous and homozygous 
carriers, suggesting this variant acts through a recessive model.  This is in agreement with the findings 
from the Swedish colorectal case-control study, in which the association observed between the 
presence of two variant MutY_rs3219489 alleles and rectal cancer was lost upon combining 
heterozygous and homozygous carriers of the allele
166
. 
In conclusion, the increased risk in breast cancer observed in our family-based case control study due 
to alleles typically associated with Lynch syndrome associated cancers suggests that while 
polymorphisms in MMR have thus far not been associated with sporadic breast cancer, deficiencies in 
this pathway may be relevant in familial breast cancer. 
There are several limitations to the candidate SNP approach utilized in the current study.  Numerous 
SNPs exist across genes involved in the MMR pathway.  Hence, although an association with breast 
cancer was observed with several SNPs, the subset of SNPs selected in this study may have excluded 
SNPs with potentially greater relevance for breast cancer.  Restricting the focus on a choice few targets 
also results in examining the impact of each SNP in isolation.  This approach does not take into 
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account the possibility that the presence of other SNPs may magnify or counteract the impact of the 
SNP under study.  Due to the small sample size of our study, we did not have enough power to assess 
possible interactions among the variants interrogated.  Even if these interactions could have been 
investigated, we would not have been able to account for the impact of SNPs not interrogated in our 
study.  This can be addressed by genome-wide association studies (GWAS), which, unlike candidate 
SNPs studies, can not only query the entire genome for all SNPs of relevance, but can also examine 
the impact of each SNP in the context of all other known variants across the genome.  However, the 
magnitude of the association observed with SNPs identified using this hypothesis-free driven approach 
has generally been small in size and findings have often failed to be replicated.  Furthermore, the 
variants identified in GWAS studies are often of unknown function, complicating the inferences that can 
be drawn from such findings.  This is in contrast to candidate SNP studies, as selection of SNPs is 
informed based on known functional implications of targets in genes and pathways of relevance, 
facilitating the mechanistic understanding underlying the observed association. 
Another area of concern is the use of a case-control study design to assess the association between 
genetic variants and the outcome of interest.  The underlying assumption of this approach is that 
observed differences in allele frequencies are related to differences in case-status.  However, 
differences in allele frequencies between populations can also arise due to differences in ancestral 
patterns and mating practices, among other factors.  If disease status is also differentiated by these 
factors, the presence of population admixture in the study population can introduce the potential for 
confounding.  Hence a major strength of the current study is the ability to minimize this type of 
confounding through the use of a family-based case-control study, ensuring that cases and controls 
stem from a genetically homogenous population. 
Still, the aforementioned limitations restrict the inferences that can be drawn from the current study.  




Chapter IV. DNA repair gene expression levels as indicators of breast cancer risk 
Abstract 
Reduced DNA repair capacity contributes to genomic instability, a hallmark of carcinogenesis.  The link 
between DNA repair capacity and cancer is especially relevant in breast cancer, where women with 
suboptimal repair capacity have been reported to have up to a five-fold increase in breast cancer risk 
compared to women with greater repair capacity.   We investigated the expression level of several DNA 
repair-related genes and their association with breast cancer risk among participants of the NY-BCFR.  
We examined RNA from viable mononuclear cells in 213 sisters (N=511 women).  A total of five genes, 
ATM, BRCA1, MSH2, MUTYH and XPC, were selected and assayed using Taqman gene expression 
kits from Applied Biosystems.   Using generalized estimating equations (GEE), we found that 
individuals in the lowest tertile of expression for ATM, a gene involved in DNA double-strand break 
repair, and MSH2, a gene involved in mismatch repair, had significantly higher odds of breast cancer 
compared to individuals in the highest quartile of expression, adjusting for age at blood draw and 
smoke status (OR=1.51, 95% CI=1.03, 2.20) and (OR=2.12, 95% CI=1.34, 3.34), respectively.  
Individuals with reduced expression of both genes had an over 3-fold increase in breast cancer risk, 
adjusted for age at blood draw and smoking status (OR=3.85, 95% CI=1.69, 8.77). Upon stratifying the 
GEE model, the observed risk due to reductions in ATM expression level was limited to women with an 
extended family history of breast cancer (pinteraction = 0.04).  Furthermore, an increase in risk due to 
reductions in XPC expression was observed among women with an age at menarche after age 13 
(OR=2.07, 95% CI=1.21, 3.54).  Finally, the observed association between reductions in ATM 
expression level and breast cancer risk is no longer significant after incorporating previously 
determined DSBR capacity of either sticky-end damage substrates (OR=1.28, 95% CI=0.15, 11.2) or 
blunt-end damage substrates (OR=1.55, 95% CI=0.15, 15.5), substantiating that deficiencies in ATM 
functionality impacts breast cancer risk through its role in DSBR.  These findings suggest that reduced 







The importance of DNA repair in breast tumorigenesis has been most clearly demonstrated by the 
identification of BRCA1 and BRCA2, genes now known to be involved in DSBR, as contributors to the 
familial presentation of breast cancer
130
.  In addition to these genes a handful of other less penetrant 
breast cancer susceptibility genes have been identified, including ATM, a gene also involved in DSBR. 
Women who have inherited mutations in either BRCA1 or BRCA2 have up to an 80% likelihood of 
developing breast cancer by age 75, while women who are carriers of mutations in ATM are at a 2-fold 
increased risk of breast cancer compared to non-carriers
131,132
.  Due to the severity of the deleterious 
effects associated with mutations in these genes, defects leading to a complete loss of function of such 
critical genes occur at low frequencies and make minor contributions towards the attributable risk 
observed within a population.  Still, these findings highlight the importance of DSBR capacity in breast 
cancer susceptibility.  A number of investigations have suggested a possible role of other repair 
pathways as well.  Several studies have reported on the presence of microsatellite instability (MSI), a 
phenotype commonly associated with deficiencies in MMR, in tumors of breast cancer cases
115 ,133
.  
Deficiencies in overall NER capacity, as assessed by various phenotyping assays, has also been 
implicated in contributing to breast cancer risk
108,109
.  These findings suggest that determination of DNA 
repair capacity may serve to identify women at elevated risk for breast cancer for targeted screening 
and intervention.  While promising, translating these findings for such a purpose is limited by the 
methods of assessment currently available to indicate repair capacity.  Validation studies in larger 
populations and subsequent development and application of a screening tool within a population-wide 
setting demand a means to detect inherent variability in repair within easily accessible surrogate 
biospecimens using a scalable methodology.  The extent of manipulation required to carry out 
phenotyping assays for the global assessment of repair, limits their utility in this desired context.  
Validated high-throughput technologies geared towards more specific endpoints within various repair 
pathways, including genotyping of SNPs, have been applied in population studies.  However, findings 
based on these studies have been mixed, with positive studies capturing only a small proportion of the 
observed effect sizes associating phenotypic assessments of repair capacity with breast cancer risk.  
This limitation of SNP studies, resulting from the inherently restrictive focus on individual factors within 
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a pathway, is further magnified by the fact that even within the context of individual genes, a variety of 
upstream factors other than genetic alterations, including epigenetic marks and transcriptional 
modifications, can impact the activity of the specific component of interest.  Hence, a more high-
throughput means of assessing repair than is feasible through phenotyping while also more 
comprehensive than genotyping may be afforded by determining expression levels of genes 
participating in DNA repair pathways.  In addition to the potential development of a risk biomarker, 
findings based on such intermediary targets can also be of etiologic consequence, filling in the gaps in 
current knowledge by linking specific upstream endpoints and repair phenotypes known to be 
associated with breast cancer. 
In this study, we assess the association between breast cancer risk and the expression levels of 5 
genes, ATM, BRCA1, MSH2, MUTYH, and XPC, known to be involved in various DNA repair pathways 














Materials and Methods 
Expression in stimulated vs. unstimulated PBMCs 
14ml of blood was collected in BD vacutainers from 5 control individuals.  The blood was immediately 
processed to isolate PBMCs via a Ficoll gradient.   A subset of the cells consisting of 5x10
5
 cells were 
pelleted and frozen at -140°C in RPMI 1640 media supplemented with 40% fetal bovine serum (FBS) 
and 15% dimethyl sulfoxide (DMSO), while a second subset of 2x10
6
 cells was grown in culture in 
RPMI 1640 media supplemented with 15% FBS, 1% Pen-strep and phytohemagglutinin (PHA, 
150uL/10mL; 5ug/mL) for 52 hr, then frozen as for un-stimulated cells.  At the time of assay, both PHA-
stimulated and un-stimulated mononuclear cells were thawed, pelleted, washed with phosphate 
buffered saline (PBS), and counted.  RNA was subsequently extracted using an RNeasy Mini kit 
(Qiagen, Valencia, CA). 
250ng of RNA was reverse transcribed using a High Capacity cDNA reverse transcription kit (Life 
Technologies, Carlsbad, CA).  The reaction consisted of 10X RT buffer, 25X dNTP Mix (100mM), 10X 
RT random primers, and MultiScribe Reverse Transcriptase.  An RT (-) control, in which the reaction 
mixture included a randomly selected RNA template and all RT reagents with the exception of the 
reverse transcription enzyme, was included as a means to assess the presence of genomic DNA 
contamination.  The thermocycling conditions followed 25°C for 10min, 37°C for 120min, and 85°C for 
5min. Level of β-actin expression was compared between stimulated and un-stimulated cells at varying 
concentrations of 2.5, 5, and 10ng in duplicate.  Expression of β-actin was assessed using pre-
designed Taqman assays:  Hs01112347_m1 (ATM), Hs01556194_m1 (BRCA1), Hs00953523_m1 
(MSH2), Hs01014856_m1 (MUTYH), Hs00190295_m1 (XPC) (Life Technologies).  In addition to the 
cDNA template, the reaction mixture also consisted of 20X Gene expression assay and 2X Taqman 
Universal Master Mix.  The thermocycling conditions including an initial incubation at 95°C for 10min, 
followed by a 95°C for 15sec and 60°C for 1min, repeated for 40 cycles.  Fluorescence signal of β -
actin was determined using a FAM-reporter labeled probe.   
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RNA isolation and reverse transcription 
PBMCs were thawed from -140°C.  DNA and RNA were extracted from the cells using an All-prep 
DNA/RNA 96 kit (Qiagen).  The plates were designed such that complete sister-sets were present on 
the same plate, while investigators remained blinded to case-control status.  Purified RNA and DNA 
were quantified using a Nanodrop 2000 (Thermo Scientific, Pittsburgh, PA). 
60ng of extracted RNA was reverse transcribed as above.  Each reverse transcribed plate also 
included an RT (-) control as described above. 
Gene expression 
Gene expression assays were run with plates set up to include 2.5ng template per sample, run in 
duplicate for each target assay and β-actin endogenous control.  Each assay was also run with cDNA 
derived from commercially purchased human total RNA (Life Technologies) as a calibrator sample, an 




The study participants consisted of 218 sister-sets (n=569) with available viable PBMCs enrolled at the 
NY- BCFR (Figure 1). 
Statistical methods 
Pearson’s chi-square tests were performed to assess the distribution of the study population according 
to selected measured variables.  Student’s t-test was conducted to compare mean case-control 
differences in relative expression level as a continuous variable.  Linear regression models were 
conducted to assess the impact of breast cancer risk factors on gene expression level on a continuous 
scale, and logistic regression models were conducted to assess the impact of these factors on 
differentiating women in the lowest tertile of expression from women with higher levels of expression.  
Breast cancer risk factors that were included in the analyses included age at blood draw, smoking 




, cut-off based on WHO definition of normal range), 
age at menarche (>13
 





age at first parity (>30
 
vs ≤30 years, nulliparous women were assigned age at blood draw), and 
extended family history (>1
 
vs 1).  Conditional logistic regression models and generalized estimating 
equations were run to assess the associations between repair gene expression level.  Risk was 
determined evaluating expression level as a continuous variable, with a change in risk assessed due to 
a 1 unit decrease in expression level, and evaluating expression level partitioned into tertiles with cut-
offs based on controls.  To adjust for potential confounding, additional known risk factors for disease, 
including age at blood draw and smoking status, were included in the models.  Effect modification was 
assessed to determine whether extended family history impacted the association between lowest tertile 
of expression in the assayed genes and breast cancer risk.  Spearman correlations were assessed 
between ATM expression levels and previously determined End-joining capacity of EcoRI-generated 
and HincII-generated damage substrates.  The presence of mediation due to ATM expression level on 
the association between end-joining capacity and breast cancer risk was analyzed using conditional 
Figure 1. Gene expression study design
The study was conducted among sisters discordant for disease with RNA 
available from MN cells.
Families at high risk of breast 
and ovarian cancer 
N=1342
Sisters discordant for case 
status
N=850 (355 sets)
Sisters discordant for case 







logistic regression.  All statistical analyses were conducted using R: A Language and Environment for 






















         
 





Selection of candidate genes 
Candidate genes were selected based on information available regarding DNA repair-related findings 
in studies conducted within the NY-BCFR and otherwise reported in the literature.  Within the BCFR, 
DNA repair-related breast cancer risk assessments spanning from high and low penetrant genetic 
alterations to overall phenotype have been conducted (Figure 2).  These findings were used in the 
current study to identify alternative intermediate endpoints that may account for a greater amount of 
variability in repair capacity than could be attributed to the previously investigated genetic components 
in the pathway while also providing greater scalability than the identified phenotypic endpoints.  Final 
selection of targets (Figure 3) was also informed based on studies in other breast cancer-relevant 
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Breast Cancer Risk

















activity (Kennedy et al, 2006) (Machella et al, 2006)
Figure 2. DNA repair-related findings within the NY-BCFR.  Deficiencies in all four repair pathways have been implicated with 
breast cancer risk in this population.  SNP genotyping studies have implicated genes involved in MMR and BER with breast 
cancer risk.  Phenotyping assays  measuring NER and DSBR have suggested suboptimal capacity in both pathways are 
associated with breast cancer risk in this population.  However genotyping of SNPs in genes in these pathways have failed to 
reveal causal genetic determinants driving the observed association.
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Biospecimen considerations 
As the current gene expression study was conducted in PBMCs, we first investigated the need to 
accommodate biospecimen-specific adjustments to the existing standardized protocol for the 
Figure 3. Candidate genes chosen for analysis (a) DSB pathway: ATM transduces the signal of DSB damage to 
downstream components of the pathway. BRCA1 acts as part of a scaffolding complex tethering participants of the 
pathway together. (b) MMR pathway: MSH2 takes part in the mismatch recognition complex.  (c)  NER pathway: XPC 
participates in the helix-distortion recognition complex. (d) BER pathway: MUTYH recognizes and removes  adenines in 
adenine:8oxoguanine mispairs.  Reprinted from Ting and Lee, 2004, Martin and Scharff, 2002, Friedberg, 2001, and 







assessment of gene expression levels.  For this purpose, a number of assay parameters were 
determined prior to commencing the study.  Since isolated cells likely have limited protein activity, we 
first assessed the need to reactivate cells through mitogen stimulation to attain detectable levels of  
transcriptional activity.  
While level of activity was higher in stimulated cells, as observed by the earlier threshold cycle, 
detectable levels of activity were also observed among un-stimulated cells.  Furthermore, greater inter-
individual variation in expression level was observed among the un-stimulated cells, suggesting that 
stimulation may artificially homogenize transcriptional activity (Figure 4).  As a result, all further 
experiments were conducted in un-stimulated cells, eliminating the need to culture cells prior to 
analysis, and, thereby, streamlining the process.   
 
An additional area of concern in regards to this cell type is ensuring that an appropriate housekeeping 
gene is selected as the endogenous control.  Housekeeping genes typically selected for this purpose in 
gene expression studies include βactin and GAPDH.  However, investigators have disputed the 
relevance of these genes as endogenous controls in studies involving PBMCs as these genes may not 
be uniformly expressed at steady-state levels in this cell population
134
.  It has been suggested that 
Figure 4. Expression levels of βactin in unstimulated and pha-stimulated PBMCs 
Level of expression was assessed within five individuals stemming from the same sister -set.








RPLO may be a more appropriate choice.  To test this hypothesis, we compared expression levels of 
βactin, GAPDH, and RPLO in stimulated and unstimulated cells in our investigation.  RPLO, while 
expressed consistently across samples with equivalent RNA template amounts, presented at levels too 
low for reliable implementation as an endogenous control.  Hence, as βactin was expressed at the 
highest levels among the tested genes, this gene was selected as endogenous control (Figure 5).   
 
 
Figure 5. Comparison of endogenous control expression level in PBMCs  
Level of expression was assessed within five individuals stemming from the same sister-
set.
βactin GAPDH RPLO
Figure 6. Expression levels of βactin at various template concentrations




Finally, limitations in availability of viable PBMCs prompted us to ascertain the limits of input RNA 
amounts feasible for detection.  As expected, higher input amounts led to higher levels of detection.  
However, as the lowest tested RNA amount of 2.5ng also yielded detectable levels of RNA, this input 
template amount was selected for the study (Figure 6). 
Study population characteristics 
The distributions of various risk factors known to be relevant to breast cancer are shown in Table 1.  No 
significant differences between cases and controls were observed based on age at blood draw, 
BRCA1/2 mutation status, ethnicity, smoke status, BMI, age at menarche or parity.   
Out of the five genes assayed, a significant difference between cases and control was observed in 
mean levels of ATM expression (Figure 7).  Differences in gene expression level were also observed 
based on additional variables (Table 2).  Significantly lower mean ATM expression level was observed 
in cases compared to controls among women with a history of smoking, women with BMI below 25 
kg/m
2
, age at first parity < 30 years of age, and borderline lower levels in cases compared to controls 
were observed among women with an age at menarche ≥ 13 years.   
While no overall case-control differences were observed for the other assayed genes, case-control 
differences were observed within certain sub-populations for several of the genes.  Cases had lower 
mean expression levels of MSH2 compared to controls among women above age 50 and among 
smokers.  Similarly, within cases, smokers had lower expression of MSH2 compared to non-smokers.  
No case control differences in expression level were observed for BRCA1, MUTYH or XPC.  However, 
among unaffected women, there was a borderline decrease in mean expression levels of MUTYH 
among women with an age at menarche prior to age 13 compared to women with a later age at 
menarche, and mean expression level of XPC was significantly higher among smokers than non-
smokers.   
The observed differences in mean expression level based on the selected variables suggest that these 
risk factors may impact the level of gene expression (Table 3).  Unaffected women with a history of 
smoking were more likely to be in the lowest tertile of expression for ATM and to have lower overall 
expression of XPC.  Women with BMI greater than 25kg/m
2
 were more likely to be in the lowest tertile 
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of expression for both BRCA1 and MSH2.  Finally, a borderline association was observed for women 





Variable No. cases (%) No. controls (%) p-valueα
(n=239) (n=298)
         ≤50 196   (65.8) 0.14
         >50 102   (34.2)
BRCA1 (+) mutation 11     (4.62) 7        (2.36) 0.22
BRCA2 (+) mutation 13     (5.46) 7        (2.36) 0.10
Ethnicity
         Non-hispanic White 127  (54.0) 142 (47.8) 0.32
         African American 5       (2.12) 8      (2.69)
         Other 103   (43.8) 147  (49.5)
Smoking Status
        Never 186   (62.4) 0.60
        Ever 96     (40.2) 112   (37.6)
BMI (kg/m2)
         <25 114   (47.7) 142   (48.3) 0.96
         ≥25 125   (52.3) 152   (51.7)
         <13 109   (46.0) 127   (42.6) 0.49
≥13 128   (54.0) 171   (57.4)
<30 151  (63.2) 201   (67.4) 0.35
≥30 88    (36.8) 97     (32.6)
         =1 137   (57.3) 193   (64.8) 0.09
         >1 102   (42.7) 105   (35.2)
α Pearson's Χ2 test
Table 1. Distribution of selected variables among sisters affected 
and unaffected with breast cancer 
Age at blood draw             
(in years)
142   (59.4)
97     (40.6)
143   (59.8)
Age at menarche               
(in years)
Age at first parity                   

































































































Figure 7. Mean case-control differences in 
level of expression of DNA repair genes
Expression levels by case status are shown for 
ATM (a), BRCA1 (b), MSH2 (c), MUTYH (d) 
and XPC (e).  Expression was generally 
observed to be lower among cases, reaching 




























































































































      






























































      






























































      
























































































































































      


























      






























































      






























































      



























      






























































      






























































      





















































































































































      













































































































































      

























































w   
      




















































                                                                                                                                                             
A
ge
   
   
   
   
   
   
   





















































































































































































































































































   
   
   




























































































































































































































   
   
   
   
   
   
   
   
































































































































































































































   
   
   




































































































































































































































   
   
   
   






































































































































































































































































































































































































































































































































Using conditional logistic regression analysis, an increased risk for breast cancer was observed among 
women in the lowest tertile of expression for ATM (OR=2.12, 95%CI=1.09,4.12) as well as MSH2 
(OR=2.75, 95%CI=1.31,5.79) (Table 4b).  Including age at blood draw and smoking status as 
covariates in the model did not appreciably alter the estimates from the crude model (Table 4b).  
Analysis conducted using GEE similarly indicated a significant association with breast cancer risk 
among women in the lowest tertile of expression for ATM (OR=1.51, 95% CI=1.03, 2.20) and MSH2 
(OR=2.12, 95% CI=1.34, 3.34) (Table 5b).  Additionally, an inverse association with breast cancer risk 
was also observed with ATM expression level as a continuous variable (OR=1.10, 95% CI=1.02, 1.18).  
Again, adjusting for age at blood draw and smoking status did not appreciably alter the estimates from 
the crude model (Table 5a).  Women who were in the lowest tertile of expression for both ATM and 
MSH2 had a nearly four-fold increase in risk compared to their unaffected sisters, adjusted for age at 
blood draw and smoking status (Figure 8).  However, no significant interaction was observed, 
suggesting an additive effect. 
To further characterize the risk associated with reduced expression of DNA repair genes, we examined 
the presence of effect modification due to family history.  Using both conditional logistic regression and 
GEE analyses, the presence of extended family history impacted the association observed between the 
lowest tertile of ATM expression and breast cancer risk (Figures 9 and 10).  The interaction term 
reached statistical significance using GEE analysis, suggesting that the association with breast cancer 
risk among women in the lowest tertile of ATM expression is largely restricted to women with an 
extended family history of disease.   
Based on previously reported findings within the sister-sets indicating an increase in breast cancer risk 
due to deficiencies in DSBR as determined by measurements of end-joining (EJ) capacity, we set out 
to determine the relationship between our assessments of ATM expression and the previously 
determined levels of EJ capacity within our study population.   A significant correlation was observed 
between ATM expression level and EJ capacity of EcoRI-generated sticky end substrates 
(r=0.23,p=0.02), while a borderline association was observed between ATM expression level and EJ 
capacity of HincII-generated blunt end substrates (r=0.20,p=0.06) (Figure 11).  Furthermore, 
incorporating EJ capacity into the model assessing the impact of ATM expression level and breast 
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cancer risk, the observed association between ATM expression and breast cancer risk was knocked 
down (Table 7). 
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Figure 8. Combined effect of reduced ATM and MSH2 expression level on breast cancer risk among sisters discordant for breast cancer
a) crude conditional logistic regression model b) conditional logistic regression model adjusted for age at blood draw and sm oke status c) crude GEE 




















































































Figure 11. Spearman correlation between  ATM expression level and EJ 
capacity of EcoRI-generated sticky ends (a) and HincII-generated blunt ends 


























ATM T1  (≤0.54) 2.12 (1.09, 4.12)
ATM T2  (0.54-1.22) 1.01 (0.57, 1.81)
ATM T3  (>1.22) 1.00 (referent)
ATM T1  (≤0.54)
ATM T2  (0.54-1.22)
ATM T3  (>1.22)
ATM T1  (≤0.54)
ATM T2  (0.54-1.22)
ATM T3  (>1.22)
Table 6. Impact of EJ capacity on the association between ATM expression level 
and breast cancer risk 
α Conditional logistic regression model assessing the relationship between tertiled levels of ATM expression 
and breast cancer risk, adjusted for age at blood draw and smoking status (ever vs. never)
δ Model includes tertiled EJ capacity of EcoRI-generated damage substrates in addition to all other 
explanatory variables of Model 1
ψ Model includes tertiled EJ capacity of HincII-generated damage substrates in addition to all other 
explanatory variables of Model 1
Model 1α Model 2δ Model 3ψ
   1.28  (0.15, 11.2)
  1.00  (0.19, 5.23)
1.00   (referent)
1.55   (0.15, 15.5)





In the current study, we demonstrate an association between reduced ATM and MSH2 expression 
levels and breast cancer risk.  Similar to the major breast cancer predisposition genes, BRCA1 and 
BRCA2, ATM is also involved in the double-strand break repair pathway as a sensor of double-strand 
break damage.  As a member of the P13K related protein kinases, the inactive serine-threonine kinase 
dimer phosphorylates into active monomers in the presence of double-strand breaks and transduces 
the signal to recruit downstream components of the pathway.   Individuals with inherited mutations 
resulting in the inactivation of this kinase activity present with ataxia telangiectasia (AT), a disorder 
whose clinical features include a predisposition to cancer, with breast cancer leading as the 
predominant sub-type among women.  While AT is a relatively rare genetic syndrome, approximately 
1% of the population are carriers of the mutation, and heterozygotic relatives of AT individuals have 
been shown to have up to a 5-fold increase in risk of breast cancer, indicating a sizable attributable risk 
in the population setting
135
. 
While reports focusing on the impact of individual, more highly penetrant variants in ATM on breast 
cancer risk have been conflicting, a mutational screen of the ATM gene in a familial-based breast 
cancer case-control study accounting for truncating, splicing and missense mutations demonstrated a 
significantly higher count of variations among cases than among controls
136
.  However, as ATM spans 
62 exons, such mutational screens seem infeasible to adopt in large-scale studies.  mRNA transcript 
levels provide an alternative means of comprehensively capturing functional activity, and several 
studies have shown reduced expression levels of ATM in breast tumors compared to normal tissue.  To 
our knowledge, only one other breast cancer case-control study has reported on ATM expression 
levels in blood.  Contrary to our findings, the study was not able to distinguish differences in expression 
levels based on case-control status
137
.  However, this may be related to the small sample size of the 
study population.   
In our study, the association between ATM expression level and breast cancer was modified by family 
history.  This is in line with findings from a mutational screen of ATM within a breast cancer case-
control study conducted at the Fred Hutchinson Cancer Research Center in which a higher mutation 





.  Furthermore, as in this study, other studies implicating ATM deficiency with breast cancer 
risk have primarily been restricted to study populations which selected for cases with a family history of 
breast cancer while population based case-control studies have failed to demonstrate similar 
associations.  This further suggests that this identified risk factor may be of particular relevance to 
women with a family history of breast cancer and may, therefore, have implications for targeted genetic 
counseling. 
MSH2 acts in conjunction with either MSH6 to recognize small loops and insertions or MSH3 to 
recognize single base mismatches in the mismatch repair pathway.  While microsatellite instability, a 
marker of MMR phenotype, has been observed in breast tumor tissues, unlike ATM, a role for the 
specific deficiency in MSH2, or other constituents of the mismatch repair pathway, has not been 
commonly reported in association with breast cancer risk.  Mismatch repair has been much more 
clearly implicated in colorectal cancer and other Lynch syndrome affiliated outcomes.  However, more 
recently, several groups have been calling for the inclusion of breast cancer among the cancer-
subtypes that constitute Lynch syndrome.  In support of this claim, a recently conducted prospective 
study within the Colon Cancer Family Registry has shown a nearly four-fold increase in risk of breast 
cancer over the general population among unaffected carriers of MMR mutations while no increase in 
risk was observed among their non-carrier relatives
139
. 
In addition to the increase in breast cancer incidence observed due to overall MMR deficiency, upon 
stratifying risk by MMR genotype, several studies have shown a heightened risk among individuals with 
mutations specifically in the MSH2 gene.  In a study following Swiss Lynch syndrome families with 
MLH1/MSH2 germline mutations, no overall increase in breast cancer incidence over the general 
population was observed.  However, a significant increase in risk was observed within families with 
MSH2 mutations
140
.  Similarly, in a study within the Colon Cancer Family Registry examining the 
incidences of cancer among individuals with a previous diagnosis of colon cancer, the nearly two-fold 




In a post-hoc analysis, upon combining women in the lowest tertile of expression for both genes, we 
observed an increase in risk above the risk associated with either gene alone.  This indicates that 
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women with deficiencies in multiple DNA repair pathways are especially prone to develop breast 
cancer. 
We did not observe differences in terms of age at diagnosis or tumor subtype based on the expression 
level of ATM or MSH2 among breast cancer cases.  However, this does not preclude the possibility that 
women with deficient expression of either gene who go on to develop breast cancer present with 
disease traits which we did not assess in the current study.  A case series study assessing the 
clinicopathologic characteristics among individuals with breast cancer from families with early-onset 
colorectal cancer determined that invasive tumors arising in cases with an MMR-deficient phenotype 
are more poorly differentiated, have a high mitotic index and are more likely to be ER/PR negative than 
cases with tumors in which no MMR deficiency was detected
142
. 
An unexpected finding following stratification was the increase in breast cancer risk observed due to 
reductions in XPC expression level among women with an age at menarche after age 13.  This is in 
contradiction with the convention that, early age at menarche, indicative of a longer exposure period to 
hormonal factors, increases risk of breast cancer.  This finding may, therefore, indicate that the means 
through which XPC mediates its impact on risk is hormone-independent. 
Finally, our findings suggest that the means through which reductions in ATM capacity impacts breast 
cancer risk is through the downregulation of DSBR capacity, substantiating the link between ATM and 
DNA repair.   In addition to establishing the etiologic mechanism through which ATM exerts its impact 
on breast cancer risk, discerning the risk due to the specific genes responsible for an observed 
phenotype also provides targets that are more readily developed into screening biomarkers than 
phenotypic endpoints.   
The risk due to EJ capacity that is explained by ATM expression level is less than substantial, as 
indicated by the correlation coefficient.   However, this may be explained by a number of factors, 
including the fact that ATM is one of multiple components involved in the DSBR pathway as well as the 
fact that ATM may exert a role in additional pathways with relevance to breast cancer.  Assay specific 
considerations may impact the level of agreement between the two findings as well.  While gene 
expression studies are indicative of transcriptional regulation, assessments of overall DNA capacity 
reflect post-translational regulation as well.  Furthermore, ATM expression levels were measured in 
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primary mononuclear cells, while EJ capacity was measured in transformed LCLs, likely reducing the 
comparability between the two assays.  Still, the knockdown in the association observed between ATM 
expression and breast cancer risk in the presence of EJ capacity indicates a vital role imparted by ATM 
expression in the performance on the DSBR pathway and ultimate breast cancer risk within this 
population.  
In summary, we report reductions in ATM and MSH2 expression level in blood is associated with risk of 
familial breast cancer.  Given a true relationship between these genes and breast cancer incidence, the 
ability to detect meaningful differences in blood indicates a potential utility as a non-invasive marker of 
risk.  Detection outside of the target site also suggests, on a mechanistic level, that the observed 
reduction in expression represents a constitutive process.  Furthermore, given the known sensitivity to 
ionizing radiation observed among AT individuals, ATM deficiency could also have prognostic 
implications, resulting in a greater likelihood of subsequent disease within this population of cases due 
to treatment of the primary tumor.   
The major strength of this study lies in the matched sister-set study design, ensuring comparability 
between cases and controls.  However, the implications of the findings from the current study are also 
hindered by several inherent limitations.  Primarily, the retrospective nature of the study precludes us 
from ruling out that our observations may be driven by reverse causality.  This issue is of special 
concern in this population, as biospecimens were often collected following onset of treatment. 
Due to the limitations in inferences that can be drawn from this study, additional studies will have to be 
conducted to validate these findings within a prospective setting.  Given the importance of these genes 
in determining risk, factors influencing the varying levels of expression of these genes also remain to 
be determined.  Finally, given an ultimate motivation to better define risk groups, further clarification on 







Chapter V: Promoter methylation levels of DNA repair genes as indicators of breast cancer risk 
Abstract 
Aberrant modulation of epigenetic patterns regulating DNA repair genes may contribute to the 
observed link between reduced DNA repair capacity and breast cancer risk.  In this study, we 
investigated the promoter methylation levels of DNA repair-related genes and their association with 
breast cancer risk among participants of the New York site of the BCFR, comparing sisters affected 
with breast cancer to their unaffected sisters.  We analyzed DNA extracted from viable mononuclear 
cells from 218 sisters (N=538 women) using pyrosequencing assays designed to target CpG islands in 
the promoter regions of BRCA1, MSH2, and MLH1.  Based on conditional logistic regression analysis, 
breast cancer risk is not significantly associated with the promoter methylation level of BRCA1 
(OR=1.09, 95% CI = 0.98-1.20), MLH1 (OR=1.18, 95% CI = 0.91-1.54) or MSH2 (OR=0.87, 95% CI = 
0.48-1.60).  We assessed spearman correlations between methylation and previously assessed 
expression levels of BRCA1 and MSH2, where we had observed a significant increase in breast cancer 
risk among women in the lowest tertile of expression for MSH2.  No significant correlation was 
observed between methylation and expression level for either BRCA1 (r=-0.05, p=0.39) or MSH2 (-
0.04, p=0.39).  These findings suggest that while MSH2 may have implications for breast cancer risk, 
as suggested by the previously observed increase in risk with decrease in expression level of MSH2, 
the lack of an association between gene promoter methylation levels and breast cancer risk and the 
lack of a correlation with the previously determined expression level of this gene, indicate that other 
mechanisms impacting the reduction in expression level of these genes may be more relevant to 
explain the observed increase in breast cancer risk.  Similarly, the lack of an association observed 
between promoter methylation levels and breast cancer risk for both BRCA1 and MLH1 suggest that 








Breast cancer is the most common malignancy among women in the developing world and claimed 
nearly 40,000 lives in the US within the past year
143
.  Reducing the burden in incidence and mortality 
will require the development of more targeted diagnostic and prognostic markers based on furthering 
the elucidation of the etiologic mechanism underlying the breakdown of normal cellular processes.  In 
addition to genetic alterations, this breakdown, characterized by the activation of oncogenes and 
knockdown of tumor suppressor genes, can also result from epigenetic aberrations.  DNA methylation, 
in which a methyl group is incorporated at the 5’ site of a cytosine residue, is the most commonly 
studied epigenetic mark
144
.  In humans, such modifications are typically restricted to CpG dinucleotides, 
which are found to cluster in the genome in CpG-rich islands
145
.  In fact, it has been established that 
cancer cells present with an altered epigenetic landscape.  These alterations follow a common pattern 
across cancer sub-types, with overall global reductions in methylation levels, facilitating genomic 
instability, as well as localized increases in methylation at specific gene promoter regions, often 
resulting in the inactivation of tumor suppressor genes
146
.   
As DNA repair genes are crucial in the maintenance of genomic integrity, downregulation of these 
genes can be critical in the onset and progression of carcinogenesis
147
.  The importance of these 
genes in cancer has long been recognized as germline mutations of several DNA repair-related genes, 
including BRCA1, MLH1 and MSH2, have been linked to the familial presentation of cancer
148–150
.  
Furthermore, tumors in individuals with deficiencies in these genes present with a distinct phenotype.  
BRCA1-deficient individuals, for example, develop breast cancers that are more likely to be basal-like, 
triple-negative and of medullary histology
151,152
.  Similarly, MLH1 and MSH2 deficient individuals 
develop Lynch syndrome related cancer sub-types with MSI, the presence of which is indicative of 
unrepaired errors due to polymerase slippage during replication
153
.  However, outside of the familial 
setting, genetic mutations account for relatively few cases, even among those who present with 
phenotypes typically associated with deficiencies in these genes
152
.  Consequently, more recent 
studies have been motivated to determine whether epigenetic downregulation of DNA repair activity 
through gene-specific hypermethylation may further contribute to risk.  Indeed, studies have reported 
on the presence of methylated promoters of BRCA1, MLH1 and MSH2, in tumors, and the 
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clinicopathological features of these tumors resemble those typically observed in cases with germline 
mutations of these genes
152,154
. 
While a number of studies have examined the methylation profile of DNA repair genes in tumors, only a 
few studies focusing on BRCA1 have investigated the presence of promoter hypermethylation of these 
genes in peripheral blood
155,151
.  Among these, only one study sought to determine case-control 
differences due to promoter methylation of BRCA1 in peripheral blood cells (PBCs). In this study, an 
increase in breast cancer risk was observed among those individuals who had detectable BRCA1 
methylation levels in blood
151
. 
To further determine the contribution to breast cancer risk attributable to the gene-specific methylation 
status of DNA repair genes, we conducted the current study to assess methylation levels in the 
promoter regions of BRCA1, MLH1 and MSH2 in PBMCs from discordant sister-sets enrolled in the 












Materials and Methods 
Study population 
The subjects for the current study included 218 sister-sets (n=569) consisting of sisters discordant for 
breast cancer enrolled in the New York site of the BCFR with available viable PBMCs (Figure 1).   
 
DNA extraction 
DNA was extracted using an All-prep DNA/RNA 96 kit (Qiagen, Valencia, CA).  The plates were 
designed such that complete sister-sets were present on the same plate, while blindedness to case-
control status was maintained.  Purified DNA was quantified using Nanodrop 2000 (Thermo Scientific, 
Pittsburgh, PA) 
Pyrosequencing 
For bisulfite conversion, 250ng of DNA from each sample in the DNA extraction plate was transferred 
onto new plates.  In addition to the intact sister-sets, each plate also contained 5% repeat samples, a 
Figure 1. Methylation study design
The study was conducted among sisters discordant for disease with DNA 
available from MN cells.
Families at high risk of breast 
and ovarian cancer 
N=1342
Sisters discordant for case 
status
N=850 (355 sets)
Sisters discordant for case 







fully methylated positive control (Millipore, Billerica, MA), a whole genome amplified negative control, 
and a non-template control.  
Bisulfite conversion of the plates was carried out using EZ-96 DNA Methylation Gold kits (Zymo 
research, Irvine, CA).  Replica plates containing 2uL template bisulfite-converted DNA were prepared 
from the original master plates. 
PCR and sequencing primers targeting CpG sites in the promoter regions of each gene of interest were 
designed using Pyromark Assay Design Software 2.0 (Qiagen) (Table 1).  A PCR reaction mixture 
including 1X Pyromark master mix (Qiagen), 1X Coral loading dye (Qiagen), and 0.2uM forward and 
reverse primers was added to the DNA template-containing replica plates, yielding a total volume of 
25uL.  The cycling conditions for the PCR reactions were as follows: 95°C 15min, [94°C 30sec, 56°C 
30sec, 72°C 30sec] x 45 cycles, 72°C 10 min. 
Following the PCR, 2uL sepharose beads (GE Healthcare, Pittsburgh, PA), 40uL Binding Buffer 
(Qiagen) in a total volume of 60uL was added to each reaction mixture.  After a 5 minute incubation 
period of vigorous shaking, the samples were transferred to a vaccum prep station, where a filter probe 
tool was used to isolate the sepharose bead-bound amplicons from the reaction mixture. The probes 
with the bound amplicons were then passed sequentially through 70% ethanol, 0.5N NaOH and wash 
buffer (Qiagen) before the vacuum was turned off and the amplicons were transferred into a 
sequencing plate, with each well containing a 25uL volume of 0.3uM sequencing primer diluted in 
annealing buffer (Qiagen). 
 



















Table 1. PCR and sequencing primers 
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 To denature the template DNA, each sequencing plate was incubated at 80°C for 2min and then 
allowed to cool to room temperature to enable the sequencing primer to bind the target region.  A 
dispensation cartridge was prepared with the required amount of nucleotides, enzyme and substrate, 
as prescribed by the Pyromark Q24 software.  Both cartridge and sequencing plate were then loaded in 
the Pyromark Q24 instrument, and the run was initiated.  Enzyme, substrate and an assay-specific 
sequence of nucleotides were dispensed by the machine as determined by the Pyromark Q24 
software.  The diphosphates released upon nucleotide incorporation serve as substrates for ATP 
generation, which in turn drives luciferase activity to generate a luminescent signal.  This signal, which 
corresponds to nucleotide incorporation, is detected as peaks in the pyrogram.  Following the run, 
percent methylation of each interrogated CpG site was calculated by the Pyromark Q24 software based 
on the ratio of the area of the peak generated by the dispensation targeting the unconverted base to 
the total area of the peaks generated by the dispensations targeting both the converted and 
unconverted base. Default parameters for peak heights expected based on the input sequence as well 
as control dispensations to indicate bisulfite conversion efficiency were used to determine quality of the 
runs. 
Statistical analysis 
For each of the three genes, percent methylation was reported as the mean value calculated across 
the interrogated CpG sites.  Wilcoxon rank sum tests were conducted to compare mean case-control 
differences in promoter methylation levels of all three genes. Pearson’s chi-square tests were 
performed to assess the distribution of the study population according to selected measured variables.   
Linear regression analysis was conducted to assess the impact of breast cancer risk factors on 
promoter methylation level on a continuous scale, and logistic regression analysis was conducted to 
assess the impact of these factors on differentiating women in the highest tertile of methylation from 
women with lower levels of methylation.  Breast cancer risk factors that were included in the analyses 





, cut-off based on the WHO definition of the normal range), age at menarchy (>13
 
vs ≤13 





years, nulliparous women were assigned age at blood draw), and extended family history (>1
 
vs 1).  
Conditional logistic regression and GEE models were run to assess the associations between promoter 
methylation levels.  Risk was determined evaluating methylation level as a continuous variable, by 
assessing the change in risk due to a 1% increase in methylation level, and partitioning methylation 
level into tertiles with cut-offs based on the promother methylation levels in the unaffected women.  To 
adjust for potential confounding, additional known risk factors for disease, including age at blood draw 
and smoking status were included in the models.  All statistical analyses were conducted using using 
R: A Language and Environment for Statistical Computing (2011), R Foundation for Statistical 






All assays included in the current study target methylation sites in CpG islands located in the promoter 
region of the genes of interest (Figures 2, 3 and 4).     
  
Pyrograms of pyrosequencing runs based on the designed assays are shown in Figure 5.  Sequencing 







Case control study 
The demographics of the study population are shown in Table 2.  No significant case control 
differences were observed based on age at blood draw, smoking status, BMI, age at first menarche, 
age at first birth or family history of breast cancer. 
Wilcoxon rank sum test revealed no significant overall differences in methylation levels between 
affected and unaffected sisters among any of the three genes (Figure 6).  Furthermore, no case control 





unaffected women, BRCA1 methylation levels were significantly higher among non-smokers compared 
to smokers, while borderline lower levels of MSH2 methylation levels were observed among non-
smokers compared to smokers.  Additionally, unaffected women with an age at menarche prior to age 
13 had higher levels of MSH2 methylation.  Among affected women, MSH2 methylation levels were 
significantly higher among those with an extended family history of disease compared to those without 
and extended family history (Table 2).   
Next we determined whether known breast cancer risk factors impact methylation levels in the genes of 




non-smokers were more likely to be in the highest tertile of methylation for BRCA1 (p=0.01). 
Women with an age at menarche below the median age at menarche in this population were  
also more likely to be in the highest tertile of methylation for BRCA1 (p=0.01) as well as MSH2 (p=0.03) 
compared to women with a later age at menarche.   
Conditional logistic regression analysis revealed no significant association between methylation levels 
of any of the three genes, measured continuously or tertiled, and case status (Table 5a).  Adjusting for 
age at blood draw and smoking status did not significantly alter any of the models (Table 5b).  Similarly, 





Finally, as gene specific promoter methylation is believed to impact cancer risk through its modulation 
on gene expression levels, we determined the correlation between these endpoints in two genes, 
BRCA1 and MSH2, for which we had previously determined expression levels in PBMCs from the 
same individuals.  As expected, an inverse relationship was observed for both BRCA1 (rho=-0.05, 
p=0.39) and MSH2 (rho=-0.04, p=0.39), indicating that higher methylation levels correspond with lower 
expression levels.  However, the observed correlations were not significant for either gene (Figure 7). 
 
Figure 5c. MSH2 pyrosequencing assay
MSH2 pyrograms of a fully unmethylated  DNA sample (top panel) and fully methylated DNA sample (middle panel).  




Variable No. cases (%) No. controls (%) p-valueα
(n=239) (n=298)
         ≤50 196   (65.8) 0.14
         >50 102   (34.2)
BRCA1 (+) mutation 11     (4.62) 7        (2.36) 0.22
BRCA2 (+) mutation 13     (5.46) 7        (2.36) 0.10
Ethnicity
         Non-hispanic White 127  (54.0) 142 (47.8) 0.32
         African American 5       (2.12) 8      (2.69)
         Other 103   (43.8) 147  (49.5)
Smoking Status
        Never 186   (62.4) 0.60
        Ever 96     (40.2) 112   (37.6)
BMI (kg/m2)
         <25 114   (47.7) 142   (48.3) 0.96
         ≥25 125   (52.3) 152   (51.7)
         <13 109   (46.0) 127   (42.6) 0.49
≥13 128   (54.0) 171   (57.4)
<30 151  (63.2) 201   (67.4) 0.35
≥30 88    (36.8) 97     (32.6)
         =1 137   (57.3) 193   (64.8) 0.09
         >1 102   (42.7) 105   (35.2)
α Pearson's Χ2 test
Table 2. Distribution of selected variables among sisters affected 
and unaffected with breast cancer 
Age at blood draw             
(in years)
142   (59.4)
97     (40.6)
143   (59.8)
Age at menarchy               
(in years)
Age at first parity                   
























































Figure 6. Mean case-control differences in 
perent methylation of DNA repair genes
Percent methylation levels by case status are 
shown for BRCA1 (a), MLH1 (b), and MSH2 
(c).  Percent methylation was generally higher 
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Figure 7. Correlation between expression level and percent methylation 








































In this study, we found no association between the methylation levels of the interrogated CpG sites in 
the promoter regions of BRCA1, MLH1 or MSH2 and breast cancer risk.  Furthermore, we found no 
significant correlation between methylation levels of either gene with previously assessed gene 
expression levels in the same individuals.   
The lack of an association in our study does not preclude the possibility that variability in the promoter 
methylation levels of these genes may be relevant to breast cancer risk and expression.  The inability 
to reveal such an association in our study may be a reflection of the inherent limitation in the utilized 
methodology, as reliable sequencing is constrained to 50 base pairs.  It is possible that the resulting 
narrowed focus on a few CpG sites fell outside a region of greater relevance.  Additionally, by design, 
primers are optimized to bind complementary regions in the template that do not contain CpG sites to 
avoid introducing methylation-specific amplification bias.  Hence the targeted regions necessarily fall 
outside more CpG-dense areas, which may be of greater relevance for the regulation of transcriptional 
activity. 
Given these considerations, we attempted to maximize the likelihood of targeting the most relevant 
sites based on previously published reports.  However, unlike our study, most of these studies have 
focused on assessing methylation levels in tissue samples.  It may be that the tumors of the cases in 
our study do exhibit increased methylation levels, however, these levels are not reflected in blood.  This 
would indicate that the epigenetic deregulation of these genes resulting in carcinogenesis did not 
originate in the germline, but were rather established later in development, resulting in a more localized 
process that is not observed in other tissues. Since detection in a non-invasive surrogate tissue, such 
as blood, is the desired specimen for screening, such markers are not suitable for this purpose.   
Snell et al did interrogate and determine case-control differences in the methylation levels of BRCA1 in 
blood, however, total white blood cells (WBC) were used as the cell source
155
.  This cell population is a 
composite of different blood cell types with unique methylation profiles, and it has been shown that 





.  Therefore, differential methylation observed in WBC may be an effect rather than a cause 
of the tumorigenic process.   
To avoid this potential bias, we restricted the analysis in the current study to PBMCs, a long-lived blood 
cell-type.   Focusing our analysis on this single cell-type, the methylation levels detected across the 
interrogated CpG sites for all three genes in our study generally fell below 5%, indicating that these 
genes may be constitutively expressed outside the target tissue, regardless of case status.   
Furthermore, our case population likely differs from the breast cancer cases selected in these 
previously reported studies.   In the Snell et al study, cases were restricted to those with tumor 
pathologies similar to BRCA1 mutant tumors but with no known BRCA1 germline mutations
155
.  If, in 
fact, BRCA1-methylation positive tumors account for only a small proportion of all cases, this would 
explain our inability to detect case-control differences in an unselected population. 
While, as in our study, the search for cancer-specific alterations in gene-specific methylation levels 
typically focus on CpG islands in promoter regions, several studies in recent years reporting on 
methylation profiles based on genome-wide scans have been challenging this convention
157,158
.  These 
studies contend that the CpG sites most differentially methylated in both tumor vs. nontumor tissues as 
well as in the bloods of cases and controls, are, in fact, in less dense CpG regions up to 2 kilobases 
away from the promoter.  In these studies, methylation levels of sites located within these “CpG shores” 
have also been shown to be more closely associated with gene expression level than sites in promoter-
region CpG islands
158
.  If indeed correct, the findings from these studies suggest that our inability to 
determine both case-control differences and significant correlation with expression levels may reflect 
our specification on sites located within CpG islands in the promoter-region of our targets of interest. 
While it is possible that expression is regulated by methylation of sites not captured in our study, the 
lack of a substantial correlation between expression levels of both BRCA1 and MSH2 and promoter 
methylation levels of these genes may also indicate that the downregulation in gene expression 
observed in our previous study is actually regulated by a mechanism other than promoter methylation 
of CpG sites.  Such processes include alternate means of transcriptional regulation, such as histone 
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modifications, or post-transcriptional processing, such as microRNA (miRNA) mediated degradation of 
mRNA transcripts. 
Hence, as our study did not determine case-control differences in PBMCs within the interrogated sites 
for the three genes of interest, future studies should explore alternative routes of expression regulation, 
including miRNAs.  Of particular interest are two DNA repair-related genes, ATM and MSH2, for which 
downregulation of gene expression was previously shown to be associated with breast cancer risk in 



















Chapter VI: Conclusions and future directions 
The studies presented in this dissertation attempted to identify endpoints across DNA repair pathways 
with the potential to develop into breast cancer screening biomarkers.  For this purpose, Chapter II 
focused on the development of an ELISA phenotyping assay to determine BPDE-DNA adduct removal 
capacity within LCLs as an indicator of overall NER activity.  In this study, we were unable to determine 
case-control differences previously observed using an immunohistochemical approach to determine 
NER capacity within the same population.  Due to the difficulties in establishing a phenotyping 
methodology applicable in a population-wide setting, we turned our focus towards more specific 
endpoints across the various repair pathways for which scalable methodologies for assessment have 
been established.   
In Chapter III, we conducted a gene expression study assessing the impact on breast cancer risk due 
to reductions in ATM (DSBR), BRCA1 (DSBR), MSH2 (MMR), MutY (BER), and XPC (NER) 
expression levels.  In this study, women in the lowest tertile of expression for MSH2 as well as ATM 
had a two-fold increase in odds of breast cancer compared to women in the highest tertile of 
expression for these genes.  Interestingly, the risk imparted by reduced expression of ATM was 
heightened among women with an extended family history of breast cancer. 
As the results in Chapter III indicated a role in breast cancer development due to transcriptional and 
post-transcriptional regulation of DNA repair gene activity, we attempted to delineate upstream factors 
which may mediate the transcriptional activity of DNA repair genes.  Hence, in Chapter IV, we 
investigated the impact on breast cancer risk due to differential promoter methylation levels of BRCA1, 
MLH1 and MSH2, DNA repair genes for which promoter methylation levels have previously been 
shown to differentiate breast cancer cases from controls.  While a majority of these studies compared 
tumor and non-tumor tissues, we found no association between methylation levels of the interrogated 
CpG sites and breast cancer risk as assessed in PBMCs.  This suggests that the sites included in our 




Finally, reduced functional activity can be mediated by means other than transcriptional regulation, 
including altered configuration of the final protein product.  As such modifications in the intended 
protein structure can be relayed through variants in the genetic code, we examined the impact on 
breast cancer risk due to the presence of polymorphisms in MMR-related genes in Chapter V.  In this 
study, we observed an increase in risk due to SNP variants in MSH2 and MutY.  A protective effect due 
to a variant in MSH3 was restricted to women without an extended family history of breast cancer. 
In summary, targets relevant to breast cancer were identified spanning several DNA repair pathways 
(Figure 1).  While ATM, a component of DSBR, has been previously established as a breast cancer 
susceptibility gene, the other targets, MSH2 and MutY, participate in pathways in which deficiencies 
are not typically linked with breast cancer.  The observation that these endpoints bear relevance to 
breast cancer risk in our studies may reflect the unique characteristics of our study population.  
Contrary to other studies which have not been able to convincingly link MMR components to sporadic 
breast cancer, the participants enrolled in the NY-BCFR stem from high-risk families.  The findings in 
this study population in addition to the role of extent of family history on modulating the risk imparted by 
several of the identified targets, suggest that susceptibility to familial breast cancer may be partially 
driven by the deregulation across DNA repair pathways.     
Caution needs to be exerted in the inferences drawn from these findings due to the limitations inherent 
in each of the conducted studies.  The null findings of the phenotyping study largely reflects the 
difficulties in developing a standardized, scalable protocol at the cost of inducing an artificial 
environment in which comprehensive capture of host activity becomes unfeasible.  Similarly, the null 
findings in the methylation study can also be partially attributed to limitations imposed by the chosen 
high-throughput platform, restricting the focus of interrogation on a few sites and possibly biasing away 
from more relevant targets. 
While the gene expression and genotyping studies did yield positive findings, the contribution to risk 
due to the identified endpoints were of moderate effect size.  This is likely due to the focus on isolated 
components within the pathways.  Additionally, both studies utilized a candidate approach, narrowing 
the focus on a few selected sites, at the exclusion of others which may yield a greater impact on risk.  
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This framework prevents accounting for the actions of other participants within the system.  As a result, 
the actual relevance of the identified targets within the true context in which they mediate their actions, 
cannot be determined from our studies.  Finally, as all findings stem from retrospective case-control 
studies, the temporality of the associations observed remains a concern.  
Still, these findings point towards additional avenues to explore for future studies within a larger, 
prospectively followed study population.  The increase in risk we observed due to deficiencies in MSH2 
and MutY, two genes most typically associated with Lynch syndrome related cancers, highlight the 
need to further clarify the heavily debated notion of whether familial breast cancer should be 
considered a constituent of the syndrome.  To this end, participants within the BCFR could be further 
characterized for the presence of suboptimal MMR activity beyond the specific endpoints chosen for 
the current studies, and those found to be deficient could be monitored for the elevated presentation of 
Lynch syndrome cancer sub-types.  
Finally, as reduced ATM activity results in a heightened sensitivity to ionizing radiation, the finding 
relating ATM deficiency with increased breast cancer risk in our study may also be of consequence to 
risk of secondary cancers due to treatment of the primary cancer.  Hence, following individuals with 
reduced expression of this gene who go on to develop breast cancer for the elevated risk of additional 
cancers following treatment will be relevant to develop a more comprehensive risk profile for those who 
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